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Antiretroviral therapy (ART) has improved the quality and duration of life for people
living with human immunodeficiency virus (HIV) infection. However, limitations in
drug efficacy, the emergence of viral mutations and the paucity of cell-tissue
targeting remain. We posit that to maximize ART potency and therapeutic
outcomes newer drug formulations that reach HIV cellular reservoirs need to be
created. In a step towards achieving this goal we discovered the aggregationinduced emission (AIE) property of the non-nucleoside reverse transcriptase
inhibitor Rilpivirine (RPV) and used it as a platform for drug cell and subcellular
tracking. RPV nanocrystals were created with endogenous AIE properties enabling
the visualization of intracellular particles in cell and tissue-based assays. The intact
drug crystals were easily detected in CD4+ T cells and macrophages, the natural
viral target cells, by flow cytometry and ultraperformance liquid chromatography
tandem mass spectrometry. We conclude that AIE can be harnessed to monitor
cell biodistribution of selective antiretroviral drug nanocrystals.
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CHAPTER 1. INTRODUCTION

1.1

Global Impact of HIV/AIDS

The HIV/AIDS epidemic began in the early 1980s and since then, 75.7 million
people have become infected with HIV with 32.7 million people have died from
AIDS-related illnesses during this period1. With the advent of antiretroviral therapy,
patient quality and duration of life have been improved significantly with a 39%
decrease in new HIV infections and a 51% decrease in HIV-related deaths
between the years of 2000 and 2019 with 15.3 million lives saved due to ART2.
Early clinical trial reports show that antiretroviral therapy has changed the lives of
patients infected with HIV3, 4. The past three decades have seen the global use of
antiretroviral therapy (ART) for those with or at risk for human immunodeficiency
virus type one (HIV-1) infection. ART has decreased disease morbidity and
mortality, in infected patients, by maintaining viral suppression to undetectable
levels5, 6. Further progress towards maintaining regimen adherence and slowing
viral transmission can now be realized through long-acting (LA) formulations and
LA slow effective release (LASER) ART prodrugs7-13. Recent advances have
shown “proof of concept” that HIV could be eliminated in live animals using LASER
ART and CRISPR/Cas9 viral excision14. However, a major obstacle remains in
demonstrating HIV-1 elimination in infected people through medical regimens
alone15-19.
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1.2

HIV-1 Pathobiology

Infection with HIV-1 begins with the entry of the virus into the host cell. The
main cellular targets of HIV are CD4+ helper T cells, macrophages, monocytes,
dendritic cells and microglial cells. Viral entry is facilitated by viral envelope
proteins namely glycoprotein 120 (gp120) and glycoprotein 41 (gp41). Binding to
the host cell is initiated by the interaction of gp120 with the cellular CD4 receptor20.
This induces a conformational change in the envelope proteins which allows for
the interaction of gp120 with either the CXCR4 or CCR5 co-receptor21. Interaction
with the co-receptor induces additional conformation changes that uncover the
gp41 that is hidden by gp120. The viral hydrophobic fusion peptide is inserted into
the host cell membrane leading to direct contact between the virus and the target
cell, following which a trimeric gp41 complex is formed, pulling the viral and cellular
membranes together, allowing the fusion of the virion and release of viral contents
into the cell22. Within the nucleocapsid of the virus are two plus-stranded RNAs
that constitute the HIV genome. These single-stranded viral RNAs are reverse
transcribed into double-stranded DNA molecules by the reverse transcriptase
enzyme, a characteristic of retroviruses23. The reverse transcription complex
(RTC) then transitions to the pre-integration complex (PIC) which is then actively
transported to the cell nucleus. The viral DNA is then inserted into the host genome
by the integrase enzyme, following which the proviral DNA is replicated along with
the host DNA as part of the host cell chromosome24, 25. The integrated proviral
DNA can then remain silent for many years in long-living memory T-cells. Proviral
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transcription is then initiated by the viral promoter located in the U3 region of the
5’ LTR. Viral transcription and RNA elongation is promoted by the initially
generated Tat protein26 and finally, the complex process of viral assembly is
carried out by the gag polyproteins along with assistance from the HIV-1 protease
to form the virions27. This progeny of virions is then released from the infected cells
by a process of budding. The released virions then undergo maturation and hijack
other target cells culminating as a major threat to the host’s immune system. The
infection leads to a marked and progressive depletion of CD4+ T cells due to their
excessive destruction28. A major depletion of CD4+ T cells occurs in the
gastrointestinal tract early on and continues throughout all stages of infection29.
Early signs of infection manifest as flu-like symptoms, but disease progression
brings plasma viremia to a set point after which patients can become asymptomatic
for extended periods. Infection is also characterized by a significant increase in
immune activation28. Without treatment, the host immune system is eventually
weakened to a point at which immune cell depletion makes the body susceptible
to opportunistic infections. Simultaneously, long-living T cells enter a latent stage
of HIV infection wherein they do not show any gene expression for several years
before being reactivated to produce infectious HIV particles. To ensure effective
and sustained eradication of HIV, these viral reservoirs need to be identified and
treated to prevent further spread of HIV infections. To address this, antiretroviral
drugs (ARVs) and viral elimination agents must be precisely delivered to CD4+ T
cell and monocyte-macrophages, the principal viral cell reservoirs.
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1.3

Targeting viral reservoir sites

The development of highly active antiretroviral therapy (HAART) enables a
greater degree of control of viral replication in HIV-infected individuals. Indeed, the
widespread use of HAART has led to a significant decline in the incidence of
AIDS30. However, while HIV treatment and therapy have dramatically changed the
course of infection in HIV-infected individuals, a critical obstacle lies in finding and
delivering therapeutics to latent viral reservoirs16, 18, 19, 31. It has been reported that
viral rebound was observed upon interruption of HAART in infected individuals in
whom extensive viral suppression was obtained32. The major latent HIV reservoir
in infected individuals has been established to be the pool of resting CD4+ T
cells33. Initially, it was believed that viral latency was largely limited to the concept
of preintegration latency which may last for a period of days until the cells become
activated leading to reverse transcription followed by integration of proviral DNA
into cellular DNA34, 35. However, it has been shown that <0.1% of resting CD4+ T
cells carry integrated provirus, i.e. postintegration latency. In this state, the reverse
transcribed proviral DNA is integrated into cellular DNA and can remain
transcriptionally silent for long periods of time36, 37. Other potential reservoirs of
HIV exist in tissues such as the brain, gut-associated lymphoid tissue, bone
marrow, and genital tract38, 39. In addition, the interaction of HIV with monocytes
and dendritic cells makes them potential viral reservoirs as well40, 41.
The imminent dangers posed by viral reservoirs demand the advancement
of delivery strategies to greatly improve the entry and accumulation of drug
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nanoformulations into viral reservoir sites. To enhance delivery to intracellular
reservoirs, various strategies such as enhancement of molecule lipophilicity or
hydrophobicity have been explored. Delivery to anatomical reservoirs sites
presents a more complex approach due to the physiological differences between
organs as well as between tissues. For these sites, prodrug strategies have been
employed to alter the physicochemical properties of drug molecules. Furthermore,
invasive administration has also been employed to surpass the blood-brain barrier,
however, long-term therapy may not be a practical option for intracerebral delivery.
Another approach that has been extensively explored for drug delivery is
nanocarrier systems. Numerous systems from liposomes42,
nanoparticles44,

45

43

to solid lipid

and polymeric nanoparticles46 have been employed. While

efficient drug delivery systems have been established, the need for a platform that
enables effective tracking of nanoparticles into cellular sub-populations still
persists. To identify and deliver antiretroviral therapies to viral reservoir sites, we
have harnessed herein, the AIE property of RPV to develop a platform that enables
drug nanoparticle tracking to immune cell sub-populations. Effective and
successful targeting of viral reservoir sites can indeed enable HIV eradication
through complete and thorough suppression of viral replication47.

1.4

Rilpivirine (RPV)

Soon after the outbreak of the HIV epidemic, the development of
antiretrovirals began. Substantial progress has been made since then as
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antiretroviral research has come a long way from Zidovudine, the first HIV drug to
be approved by the US FDA48 to Fostemsavir, an attachment inhibitor that received
US FDA approval July 202049. With the understanding of HIV and its life cycle,
new and various targets were identified for the development of novel antiretroviral
compounds. In 1995, the first class of HIV drugs, protease inhibitors, was created
followed closely by the non-nucleoside reverse transcriptase inhibitors in 199650,
51

. Over the next few years, new classes of HIV compounds emerged such as

fusion inhibitors52, entry inhibitors53 and integrase inhibitors54, the latest being
attachment inhibitors49, 55. As HIV understanding advanced and antiretroviral drug
development progressed, it became apparent that combination antiretroviral
therapy was necessary for effective management of HIV, to avoid the development
of resistance and to reduce morbidity and mortality rates56,

57

. Thus, further

advances in antiretroviral treatment involved the development of single multi-drug
tablets such as Atriplaä ( efavirenz, emtricitabine and tenofovir disoproxil
fumarate)58 and Biktarvyâ ( bictegravir, emtricitabine and tenofovir alafenamide)59.
In 2011, a new non-nucleoside reverse transcriptase inhibitor (NNRTI),
rilpivirine (RPV), was approved by the FDA. NNRTIs are non-competitive inhibitors
and act by binding to a hydrophobic pocket near the catalytic site of reverse
transcriptase (RT)13. With antiviral activity in the sub-nanomolar range (0.73 nM),
RPV is a highly active molecule from the diarylpyrimidine family of NNRTIs60. RPV
is active against a wide variety of NNRTI resistant HIV strains due to its flexibility
of binding at the allosteric site of HIV-1 RT61. The broad-spectrum activity and
presentation of fewer adverse effects differentiates RPV from other NNRTIs such
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as Nevirapine (NVP) and Efavirenz (EFV) that have been reported to generate
hepatotoxic and neuropsychiatric side effects respectively62, 63.
In our efforts to develop platforms that could reach viral reservoir sites, we
uncovered yet another property of RPV that distinguishes it from other NNRTIs.
We found that RPV exhibits the phenomenon of aggregation-induced emission
(AIE). In its aggregated form, RPV emits blue fluorescence when excited by UV
light. RPV proved to be an excellent candidate for ARV tracking as it is used as
part of LA antiretroviral regimens and its mechanism of action involves interference
with the early-stage life cycle of HIV replication. To elucidate the RPV AIE property
for use in drug tracking, drug nanocrystals (RPV-NC) were synthesized, enabling
quantitative analysis of cell targeting by flow cytometry. We were successful in
affirming particle biodistribution by ultra-performance liquid chromatographytandem mass spectrometry (UPLC MS/MS) analysis of the drug in CD4+ T cell
and monocyte-macrophage populations. We contend that harnessing the AIE
properties of RPV for drug biodistribution could speed the further development of
LA ARVs and in success for viral elimination strategies.

1.5

Aggregation Induced Emission (AIE)

AIE is a photophysical phenomenon that was first discovered in 200164. AIE
is a phenomenon wherein non-emissive molecules can fluoresce upon excitation
when in the form of aggregates or a crystal lattice

64-67

. To date, a plethora of

molecules have been characterized for their AIE properties and several more have
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been newly synthesized or discovered. One such prototypical molecule is
Tetraphenylethylene (TPE) that has been widely studied and characterized for its
AIE properties

68-71

. Another organic molecule that has been characterized for its

AIE properties is hexaphenylsilole (HPS). Similar to other AIEgens, HPS is nonemissive when its molecules exist in a solution form. However, upon aggregation
in an aqueous medium, HPS is induced to emit a strong fluorescence64, 72. Various
other molecules have been synthesized or derivatized to molecules that exhibit the
AIE phenomenon, showing a strong fluorescence upon aggregation in various
forms73, 74. The mechanism behind AIE has been under extensive investigation,
yielding

several

possible

working

mechanisms

that

include

restricted

intramolecular rotation (RIR), restricted intramolecular vibrations (RIV) and
restricted intramolecular motions (RIM) which involves both RIR and RIV 64, 67. The
use of these AIE molecules spans a wide range of applications from chemical
sensors to biological imaging probes in diagnosis and therapy. GFP-loaded
perfluorocarbon nanoemulsions (PFCs) that enabled the visualization of these
nanoparticles in CIR+ cells using Fluorine magnetic resonance imaging were
developed75.

Another

report

describes

the

fabrication

of

programmed

nanoparticles that can track dendritic cells in vivo via the use of PLGA NPs
containing near-infrared fluorophores76. Technological advancements can now
facilitate the tracking and visualization of single nanoparticles in living cells using
up-conversion particles that can transform low energy near-IR photons into highenergy visible emissions77,

78

. Advancement of AIE has attracted the

implementation of AIEgens in various technological applications79. Plentiful AIE
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molecules are now being used as biological probes, in biomolecular sensing and
biological imaging, as chemical sensors and in optoelectronic systems64, 80-82. Cao
et. al demonstrated the use of an AIE luminogen for real-time tracking of extracellular vesicles in liver regeneration83. Photosensitizers, theranostic nanocarriers
for cancer and bioprobes for real-time cell monitoring are some examples of the
various applications of AIE84-87. Another exciting application of AIE involves the
use of AIE dots which comprise of organic biocompatible nanoparticles with a
dense core of AIE fluorogens. These AIE dots serve great potential as theranostic
nano lights in biomedical applications88, 89.
While various methods involving magnetic and gold nanoparticles have also
been explored for cellular tracking90, 91, we demonstrate herein, for the first time,
tracking of intact antiretroviral therapeutic nanoparticles in CD4+ T cell reservoirs
using AIE. Because AIE is a phenomenon that is expressed only when the
molecule is in an aggregated state64, 67 such as in a nanoparticle, this platform
enables the assessment of nanoparticle integrity as well as tracking in cellular
subpopulations of interest such as the CD14+ macrophages and CD4+ T cells.

1.6

ARV Biodistribution (BD) and Pharmacokinetics (PK)

Since the discovery and subsequent development of antiretroviral therapy,
substantial

efforts

have

been

made

to

study

the

biodistribution

and

pharmacokinetics of these compounds and their formulations. The determination
of the BD and PK of a drug candidate are fundamental components of drug product
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development. Over the years, results from multiple clinical trials have published
the evaluation of the efficacy of different antiretroviral-based strategies for the
treatment and prevention of HIV92. The study of BD and PK is the principal
component of drug and/or nanoformulation evaluation.
BD and PK have also been used to optimize antiretroviral drug-drug
interactions in the treatment of HIV93,

94

. Govil et. al deduced the mucosal

pharmacokinetics of the ARV Tenofovir to create inferences about PK metrics and
draw multiparametric relationships95. Additional biodistribution studies carried out
by Kevadiya et. al demonstrated that rod-shaped nanoparticles facilitate ARV drug
biodistribution in HIV susceptible calls and tissues96. These nanoparticles mimic
the size, shape and surface properties of long-acting prodrug nanoformulations
and enable real-time assessment of nanoparticle biodistribution in anatomical
reservoir sites of HIV such as the liver, spleen, lungs and lymph nodes. While
traditional PK methods require end-point animal sacrifice to determine drug
concentrations in specific organs, they have proposed herein, a method to
determine nanoparticle accumulation in organs by real-time bioimaging tests96.
Furthermore, there is a need for useful pharmacokinetic models to predict the
efficacy of compounds developed for HIV therapy. To address this need, many
pharmacokinetic/pharmacodynamic (PD) models have been created to assess the
efficacy of HIV drugs97-99. However, while PK/PD modeling has provided new
insight into the efficacy and biodistribution of new compounds, challenges still
abound100, 101.
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To overcome the limitations of accurate PK predictions, effective drug
delivery to viral reservoir sites and methods to determine drug concentrations and
track drug delivery, we have developed herein, a nanoparticle platform that
enables successful tracking of fluorescent nanoparticles in cellular subpopulations.
The formulation of RPV-NC ensures that RPV is in a stable, aggregated form with
the molecules arranged in a definitive crystal lattice so as to emit optimal
fluorescence upon excitation by UV light. Furthermore, the ability to track and sort
immune cell types based on surface biomarkers enables us to separate the cellular
sub-populations to determine the effective drug concentration in each of the sorted
cell types. Fluorescence-concentration correlations have shown the accuracy of
these assays, proving that the fluorescence emitted by the nanocrystals coincides
with the concentration of drug present. This work puts forth several possibilities in
the field of bioimaging and AIE with the potential to substantially improve
biodistribution and therapy using AIE to track drug delivery to viral reservoir sites,
as we move forward in the direction towards HIV eradication.
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1.7

Figures

Figure 1.1 HIV life cycle and development of latency.102
Cellular invasion by HIV begins with the binding of the virus particle to the CD4+ T
cell receptors leading to fusion and entry of viral proteins and RNA. Viral reverse
transcriptase then produces viral DNA by reverse transcribing viral RNA. Transport
to the nucleus is followed by integration into the host cell genome by HIV integrase.
Viral DNA may enter a stage of pre-integration latency and remain silent until
activation leads to integration and subsequent transcription. Alternatively,
integrated viral DNA may enter a stage of post-integration latency creating silent
viral reservoirs. Upon activation of these reservoirs, viral RNA is produced by
transcription and undergoes splicing and assembly with viral proteins to form new
virions. Figure adapted from Lusic, M., Siliciano, R. Nuclear landscape of HIV-1
infection and integration. Nat Rev Microbiol 15, 69–82 (2017).
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Anatomical reservoirs

Cellular reservoirs

Figure 1.2 HIV viral reservoir sites.37, 103
The resting CD4+ T cell pool has been established as the major cellular reservoir
of HIV. Macrophages, monocytes and dendritic cells are also other potential
reservoir sites. Anatomical reservoir sites include the brain, gut-associated
lymphoid tissue, bone marrow, and genital tract38, 39.
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Figure 1.3 Rilpivirine (R278474) in the NNRTI-binding pocket (modeled
structure).60
The structure of Rilpivirine within the nonnucleoside binding site of RT. The
improved activity of RPV on wild-type and mutant HIV-1 strains may be due to a
specific interaction involving the cyano group of the molecule and the indole ring
of Trp229 on RT60.
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Figure 1.4 The phenomenon of Aggregation Induced Emission.
AIE is a phenomenon wherein non-emissive molecules are able to fluoresce upon
excitation when in the form of aggregates or in a crystal lattice. 64-67
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Figure 1.5 Visualizing the AIE property of Rilpivirine.
In an aggregated form, as in RPV-NC, RPV is highly emissive with a blue
fluorescence upon excitation by UV light. This is due to the RIM that arises from
the restricted rotation of p rings in RPV crystals that leads to fluorescent emission.
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CHAPTER 2. SYNTHESIS AND CHARACTERIZATION
OF RPV-NC

2.1

Introduction
The major target cells for HIV infection are the CD4+ T cell and the monocyte-

macrophage 104-106. Thus, detection of viral suppressive agents in these cells could
prove valuable towards improving therapeutic and eradication designs. Indeed, the
AIE properties of RPV enables drug tracking by fluorescence emission. This ability
was affirmed by TEM, UPLC-MS/MS, flow cytometry and confocal microscopy
(Table 2.1).
RPV exhibits AIE when in an aggregated form because of the restriction of
intramolecular motion. A stable, uniformly ordered aggregate structure allows for
optimal emission of fluorescence upon excitation. Hence, RPV-NC were
formulated by a method of antisolvent precipitation107-109 using a Smart
nanotechnology bottom-up top-down approach110. The process of antisolvent
precipitation allows for rapid crystallization of RPV into a uniform crystal structure.
The micron-sized particles are then coated with a lipid film. A stable aggregate
ensures maximum restriction of intramolecular motion and hence emission of
fluorescence. Following stabilization, the particles are subjected to high-pressure
homogenization111 to obtain nanoparticles with a hydrodynamic diameter of about
250 – 300nm. The process of high-pressure homogenization allows for the
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formation of compact, highly stable nanoparticles with a narrow polydispersity
index.
The development of an AIE molecule involves various tests of photo
properties and fluorescence emission112. Hence, RPV-NC were thoroughly
characterized for physicochemical properties, fluorescence properties, as well as
crystal structure. Physicochemical characterization involved TEM, XRD and TGA
analyses along with stability studies by determination of PDI and hydrodynamic
diameter.

Characterization

of

fluorescence

properties

involved

confocal

microscopy images, absorption and emission spectra, photostability studies and
measurements of fluorescence intensities in different conditions. The crystal
structure was also elucidated in detail by x-ray crystallography. Thus, a stable
platform that can be used for several potential bioimaging applications was
produced.
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2.2

Methods

2.2.1 Reagents
RPV was purchased from Hangzhou Bingo Chemical Co., Ltd. (Hangzhou,
ZJ, China). 1, 20-Distearoyl-phosphatidylethanolaminemethyl-polyethyleneglycol
conjugate 2000 (DSPE-PEG2000) was obtained from Corden Pharma International
(Plank Stadt, Germany). L-α-phosphatidylcholine (from egg yolk) Chloroform,
Dimethyl sulfoxide, N-butanol and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazolium bromide (MTT) from Sigma Aldrich (St. Louis, MO, USA).

2.2.2

Synthesis of RPV-NC
Formulation of RPV-NC followed a bottom-up top-down approach

110

wherein micron-sized crystals of RPV were prepared and then subjected to size
reduction to obtain nanocrystals. Approximate 366 mg of RPV was dissolved in
400 ml of methanol and heated for 1 hour at 70°C for a complete dissolution of
RPV. To obtain a saturated solution, solvent volume was reduced under vacuum
in a rotavapor (Heidolph, Hei-VAP Precision, G3B Vertical, Schwabach,
Germany). The saturated solution was then added to 300 ml of deionized water at
4°C in a sonication bath under rapid stirring at 2500 rpm (IKA RW 20 Digital
overhead stirrer, IKA Works, Inc., Wilmington, NC, USA). The formulation was
sonicated and stirred rapidly for 15 min. The white, uniform suspension obtained
was purified by ultra-centrifugation at 6000 g for 30 min (Thermo Scientific™
Sorvall™ LYNX 4000 superspeed centrifuge, Waltham, MA, USA). The solid pellet
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was lyophilized overnight. For the preparation of the lipid film, 200 mg of L-αphosphatidylcholine and 100 mg of DSPE-PEG2000 were dissolved in a
chloroform/hexane mixture (5:1 v/v) contained within a round-bottomed flask and
evaporated to form a thin film using a rotavapor. The films were dried overnight to
ensure complete removal of organic solvents. Lyophilized RPV crystals were
dispersed in 15 ml of endotoxin-free water, added to the prepared lipid film and
sonicated for 5 min to obtain a uniform surface coating. The mixture was then
homogenized at 20,000 psi in an Avestin EmulsiFlex-C3 high-pressure
homogenizer (Ottawa, ON, Canada) until the desired particle size was reached
(~320 nm). Suspensions were stored at room temperature in amber vials for light
protection.

2.2.3 Transmission electron microscopy (TEM), powder X-ray diffraction
(XRD), thermal analysis and stability measurements
Nanoparticle morphology was analyzed by TEM. Nanoparticle suspensions
were dried on a copper grid at room temperature and bright-field images were
taken with two second exposure times using the Tecnai G2 Spirit TWIN electron
microscope (FEI, Houston, TX, USA) operating at 80 kV. Images were acquired
with an AMT digital imaging system 113. Analyses were carried out with XRD using
a PANalytical Empyrean diffractometer (PANalytical, Inc., Westborough, MA,
USA). This was performed in the 2θ range of 2– 70° with Cu-Kα radiation (1.5418
Å) at 40 kV, 45 mA setting. The incident beam path used a mask of 20 mm and a
divergence slit of 1/32°. A layer of the powder was placed on a zero-background
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silicon plate. The sample holder was then spun at the rate of 22.5 deg/sec. During
data collection, the solid state PIXcel3D detector (PANalytical, Inc., Westborough,
MA, USA) scanned at a rate of 0.053 deg/sec. The PIXcel3D used a beam
monochromator used to improve the signal to noise ratios. Thermogravimetric
analysis was performed under a nitrogen flow of 20 ml/min at a temperature of 30–
600°C and a heating rate of 10°C/min (TGA 209 F1 Libra, Netzsch-Gerätebau
GmbH, Selb, Germany). The stability of the RPV-NC nanoparticle suspension was
assessed for 3 weeks at 4°C recording hydrodynamic particle size distribution.

2.2.4 Spectral measurements and drug quantifications
For confocal microscopy, single crystals of RPV-NC were imaged using a
20x oil objective on an LSM 710 confocal microscope (Carl Zeiss Microimaging,
Inc., Dublin, CA, USA). Zeiss LSM 710 Image browser AIM software version 4.2
was used to determine pixel numbers and the mean channel intensities.
Absorption spectra of dilute RPV suspensions were recorded on Thermo Scientific
Evolution 220 spectrophotometer in quartz cuvettes with the optical path length of
1 cm. Fluorescence spectroscopy measurements were performed at 350 nm
excitation by SpectraMax® M3 Multi-Mode Microplate Reader (Molecular Devices,
LLC, Sunnyvale, CA, USA), or on the Fluoromax 4 (Horiba Jobin Yvon, Kyoto,
Japan) fluorometer (λexc=335 nm) in quartz cuvettes with the optical path length of
1 cm. Fluorescence quantum yields were determined using quinine sulfate in 0.5
M H2SO4 as a standard (φ=0.546

114

). The photostability of RPV-NC was studied

under a UV lamp (4 W, λ=365 nm, broadband filter) with constant stirring. Analysis
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of RPV concentrations was carried out by UPLC using a Waters Acquity UPLC HClass System with TUV detector and Empower 3 software (Waters, Milford, MA,
USA). Sample separation was done on a Phenomenex Kinetex 5 μm C18 column
(150 X 4.6 mm, Phenomenex Ltd., Torrance, CA, USA) using an isocratic mobile
phase of 65% 50 mM KH2PO4, pH 3.2 / 35% acetonitrile at a flow rate of 1.0 ml/min
and detection at 285 nm. Drug content was quantitated by comparison of the peak
area to those of known standards (0.05–50 µg/ml in methanol)

115, 116

. All flow

cytometry data were acquired on a BD LSR II flow cytometer and analyzed using
FLOWJO analysis software v10.2 (Tree Star, Ashland, OR, USA) and BD
FACSDiva™ Software v8 (BD Biosciences, San Jose, CA, USA). Untreated and
single stained controls were used to assign gates for nanoparticle positive
populations. Light microscopy images of the particles were taken using a Nikon
TE300 microscope (Nikon Instrument, Inc., Melville, NY, USA) with a 20x objective.
Polarized microscopy images were taken using an Olympus BX51 (Olympus
Scientific Solutions Americas Corp., Waltham, MA, USA) polarizing microscope at
90° polarized light.

2.2.5 Single-crystal x-ray diffraction
Single crystals for x-ray diffraction were prepared from a saturated solution
of RPV in a mixture of dimethylsulfoxide (DMSO; 75%) and n-butanol (25%). A
suitable crystal was selected and mounted on a Kryoloop using paratone oil on an
Xcalibur, Onyx, Ultra Diffractometer (Oxford Diffraction Limited, Oxfordshire, UK).
The crystal was kept at 100 K during data collection. Using OLEX2117, the structure
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was solved with the SHELXS118 structure solution program using Direct Methods
and refined with the SHELXL119 refinement package using Least Squares
minimization.

2.2.6 Statistics
For all studies, data were analyzed using GraphPad Prism 7.0 software (La
Jolla, CA) and presented as the mean ± the standard error of the mean (SEM).
For comparisons of two groups, Student’s t-test (two-tailed) was used. HIV-1 RT
activity and HIV-1p24 staining were analyzed by one-way ANOVA with Bonferroni
correction for multiple comparisons. Extreme outliers beyond the 99% confidence
interval of the mean and 3-fold greater than the SEM were excluded. Significant
differences were determined at P < 0.05.
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2.3

Results

2.3.1 RPV-NC preparation
RPV-NC were formulated by Smart nanotechnology

110

(Figure 2.1 A).

Micron-sized particles were prepared by anti-solvent precipitation.107-109 A
consistent molecular RPV crystal structure was achieved. Based on RPV solubility
in methanol, a saturated drug solution was prepared by heating. The solution was
then rapidly added to ice-cold water under bath sonication and high-speed
shearing. The homogenous suspension of particles was purified by high-speed
ultra-centrifugation and freeze-dried. Lyophilized particles were dispersed in water
and coated with a lipid film containing DSPE-PEG2000 and phosphatidylcholine (αPC) to impart stability and lipophilicity. The suspension was subjected to highpressure homogenization for size reduction and nanocrystal formation.111

2.3.2 Physicochemical characterization
The physicochemical properties, fluorescence and structural features of
these nanocrystals were studied by various analytical techniques. TEM images
taken before homogenization showed micron-sized, ‘flower-shaped’ crystals
accumulated in clusters Figure 2.1 B and C

120

. Figure 2.1 D demonstrates that

the nanocrystals had a uniform shape and smooth surface with a particle size of
approximately 200 nm after homogenization. To ensure that crystal structure was
retained, powder x-ray diffraction (XRD) analysis was performed for native RPV
and for RPV crystals before and after homogenization. As shown in Figure 2.1 E,
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F and G, the characteristic diffraction peaks of native RPV (Figure 2.1 E) at 12.4°,
17.5°, 20.1°, 21.1° and 27.9° at 2° positions were maintained in the RPV crystals
before (Figure 2.1 F) and after homogenization (Figure 2.1 G). This was also seen
in RPV-NC after storage for 21 days at 25°C (Figure 2.2). The lack of a shift in the
x-ray diffraction patterns demonstrates that the crystalline nature of native RPV in
the free drug form was preserved in the microcrystals as well as in the
homogenized nanoparticles. The thermal stability of the formulated and native drug
was shown by thermogravimetric analysis (TGA) analysis. The isothermal heating
distribution curve of TGA showed an endothermic peak at 444.22°C and 442.78°C
due to the complete degradation of native RPV and RPV-NC, respectively. TGA is
represented as a derivative thermal analysis (DTA) in Figure 2.1 H and shows the
unchanged thermal properties of RPV-NC with respect to native RPV. The stability
of RPV-NC in suspension at room temperature was monitored by dynamic light
scattering (DLS). The zeta potential was found to be -24.9mV and as shown in
Figures 2.1 I and J, the particle size, represented by hydrodynamic diameter, and
polydispersity index (PDI) remained constant at 320 nm and 0.2, respectively, for
a period of 21 days.

2.3.3 AIE properties
In its aggregated form, RPV emits blue fluorescence when excited by UV
light. This unique property can be used to monitor particle integrity. The AIE
properties of RPV were characterized by various methods

64, 70

. Confocal

microscopy images of the RPV crystals overlapped with bright-field microscopic
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images displayed uniformity of fluorescence emission (Figure 2.3 A). Since RPV
is freely soluble in methanol, the AIE phenomenon of RPV-NC was studied in
various ratios of water/methanol. The shift towards longer wavelengths and the
broader width of the peak suggests that it should be attributed to the absorption of
the RPV aggregates. The isosbestic point at approximately 325 nm supports the
conclusion that these two absorption peaks are related (Figure 2.3 B). Similar
conclusions can be made from the analysis of the RPV emission spectra (λexc=335
nm) in the same solvent systems (Figure 2.3 C). There is no detectable
fluorescence from RPV in its solution in methanol. Upon the increase of water
content to 50%, blue fluorescence rises with a maximum at 385 nm. It reaches its
maximum intensity at ~70% water content, and then somewhat decreases,
potentially due to partial quenching induced by interactions with water
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.

Measurements of fluorescence quantum yield in solvent systems with varying
amounts of methanol (%v/v) yielded a sigmoidal curve with a high goodness of fit
(R2 = 0.9981; Figure 2.3 D), a trend that was visually discernable (Figure 2.3 E).
Analysis of RPV levels in supernatants of these samples showed an inverse
relationship between drug concentration and fluorescence intensity (Figure 2.3 F).
As the particles dissolve rapidly in 50% methanol, the fluorescence intensity drops
significantly.
Further characterization of the AIE properties and its fluorescence stability
important for prospective theranostic applications was carried out by measuring
fluorescence intensities in different conditions. Emission of RPV-NC remained
stable over a pH range of 2 to 14 but rapidly declined at pH 1 due to the complete
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disintegration of RPV aggregates (Figure 2.3 G). The photostability studies
revealed that the fluorescence intensity of RPV-NC only decreases by
approximately 30% over the course of 6 hours of constant irradiation (Figure 2.3
H). The associated absorption and emission spectra (Figure 2.4) do not show any
apparent photooxidation or other degradation processes that affect RPV-NC
performance. These observations demonstrate that RPV-NC exhibit AIE.

2.3.4 Elucidation of crystal structure
Several agents that exhibit the AIE property via RIM have previously been
reported

64, 65, 67

. To understand the mechanism of AIE exhibited by RPV, single-

crystal x-ray diffraction studies were performed (Figure 2.5 C). Single crystals of
RPV were grown from a mixture of two solvents to obtain clear micron-sized
crystals (Figure 2.5 A). By polarized microscopy, the optically anisotropic
character of the crystals was observed (Figure 2.5 B). X-ray crystallographic data
revealed that two RPV molecules crystallized in a single cell unit (Figure 2.5 D).
Displacement parameters, structure refinement and crystal data from x-ray studies
are described (Table 2.2 – 2.8). Examination of the packing diagram revealed
several close CH-p interactions for adjacent RPV molecules within the crystalline
lattice. These contacts ranged from 2.96 - 3.5 Å. Similar intramolecular distances
were observed for hexaphenylsilole (HPS) whose crystal structure showed
intramolecular distances between C-H bonds and p rings of 2.587 - 3.642 Å 64, 72.
Taken together, these data suggest that restricted rotation of p rings in RPV
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crystals enable fluorescent emission by a RIM mechanism similar to that observed
in other compounds 65.
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2.4

Discussion
The AIE properties of RPV were hence discovered and studied in depth. To

confer a purpose to the AIE property of RPV, RPV-NC were synthesized by a
Smart nanotechnology bottom-up top-down approach involving anti-solvent
precipitation to obtain stable, uniform nanocrystals. These nanocrystals were
observed to be stable for a period of weeks. Nanocrystal morphology and surface
topology was studied by TEM and SEM, respectively. Other characteristics such
as thermal stability and the crystalline nature of the molecule within the
nanocrystals were also studied.
Determination of AIE properties involved qualitative assessments of large
micron-sized crystals of RPV by confocal microscopy to be able to visualize the
fluorescence emission of the crystals upon excitation by UV light. Spectral
measurements were also carried out to determine the maximum wavelength of
emission as well as the absorption and emission spectra. Thus, a new property of
the antiretroviral compound, RPV, was established.
Crystal structure elucidation by x-ray crystallography uncovered several
intramolecular interactions in the nanocrystals. The distances observed between
the C-H bonds and p rings of RPV molecules show that significant intermolecular
interactions exist between adjacent molecules. These non-covalent interactions
hold the RPV molecules together, stabilizing the crystal packing and restricting the
rotational motion of the phenyl rings. While similar intramolecular distances have
been observed in other AIEgenic molecules, the intermolecular interactions in RPV
have a similar effect on the intramolecular rotations. Hence, the restricted rotation
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of p rings in RPV crystals enables fluorescent emission by a RIM mechanism
similar to that observed in other compounds 65.
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2.5

Figures

32
Figure 2.1 RPV-NC synthesis and physical characterizations.
(A) Schematic representation of the Smart nanotechnology used to formulate
RPV-NC by bottom-up and top-down approaches. (B) Low and (C) high
magnification TEM images showing the morphology of RPV crystals made by antisolvent precipitation. (D) TEM image of RPV-NC shows uniform surface
morphology after homogenization. (E, F, G) XRD patterns of native RPV, RPV-NC
before and after homogenization, respectively. (H) TGA analysis of native RPV
and RPV-NC. (I) The hydrodynamic size distribution of RPV-NC is shown by DLS
(average size ~ 320 nm). (J) The stability of RPV-NC was determined by size and
PDI measurements over a three-week time period.
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Figure 2.2 XRD pattern of RPV-NC.
The characteristic diffraction peaks of native RPV at 12.4°, 17.5°, 20.1°, 21.1°
and 27.9° at 2° positions were maintained in RPV-NC after storage for 21 days at
25°C.
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Figure 2.3 Fluorescence characteristics of RPV-NC.
(A) Confocal and bright-field images of RPV-NC merged to show fluorescence
distribution. (B) Absorption spectra of RPV-NC in water/methanol ratios. (C)
Corresponding fluorescence spectra of RPV-NC in water/methanol ratios. (D)
Fluorescence quantum yield in water/methanol ratios. (E) RPV-NC in
water/methanol ratios upon UV excitation. (F) Fluorescence (FL) intensity and
concentration of RPV in various methanol/water ratios. (G) Fluorescence intensity
of RPV-NC at different pH. (H) Photostability of RPV-NC.
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Figure 2.4 Photostability associated spectra.
(A) Absorption spectra of RPV-NC in 100% water over 6h. (B) Corresponding
fluorescence emission spectra of RPV-NC.
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Figure 2.5 Single crystal x-ray RPV-NC crystallography.
(A) Light microscopy images of single crystals of RPV. (B) Polarized microscopy
images of single crystals of RPV. (C) Schematic representation of single crystal xray crystallography setup. (D) Molecular conformation of RPV in RPV-NC showing
the intermolecular CH-p interactions.
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2.6. Tables

Table 2.1 Methods of analysis of RPV AIE in cells and in rodent animal
models.
The table names the tests used to affirm RPV AIE. TEM, UPLC-MS/MS, flow
cytometry and confocal microscopy tests were used for drug tracking using
fluorescence emission tests.

In vitro

Models

Dose

Macrophages
T cells

100µM

In vivo

Sprague-Dawley rats
PBL mice
Humanized mice

45mg/kg

Methods of Analysis
TEM

UPLC-MS/MS

Flow cytometry

Confocal microscopy

+

+

+

+

+

+

+

+

-

+

-

+

-

+

-

+

-

+

+

-
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Table 2.2 Crystal data and structure refinement for Rilpivirine.

IDENTIFICATION CODE
EMPIRICAL FORMULA
FORMULA WEIGHT
TEMPERATURE/K
CRYSTAL SYSTEM
SPACE GROUP
A/Å
B/Å
C/Å
Α/°
Β/°
Γ/°
VOLUME/Å3
Z
ΡCALCG/CM3
Μ/MM-1
F(000)
CRYSTAL SIZE/MM3
RADIATION
2Θ RANGE FOR DATA
COLLECTION/°
INDEX RANGES
REFLECTIONS COLLECTED
INDEPENDENT REFLECTIONS
DATA/RESTRAINTS/PARAMETERS
GOODNESS-OF-FIT ON F2
FINAL R INDEXES [I>=2Σ (I)]
FINAL R INDEXES [ALL DATA]
LARGEST DIFF. PEAK/HOLE / E Å-3

Rilpivirine
C22H18N6, 2(C2H6OS)
366.4 + (2*78.13) = 522.68
100
triclinic
P-1
8.41354(18)
11.8546(2)
13.7483(2)
79.7407(16)
89.0890(16)
80.1013(17)
1329.08(5)
2
1.306
2.098
552.0
0.25 × 0.25 × 0.1
CuKα (λ = 1.54184)
6.534 to 151.482
-10 ≤ h ≤ 10, -14 ≤ k ≤ 14, -17 ≤ l ≤
17
46467
5442 [Rint = 0.0559, Rsigma = 0.0235]
5442/0/331
1.061
R1 = 0.0507, wR2 = 0.1334
R1 = 0.0551, wR2 = 0.1415
1.82/-0.60
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Table 2.3 Fractional Atomic Coordinates (×104) and Equivalent Isotropic
Displacement Parameters (Å2×103) for Rilpivirine. Ueq is defined as 1/3 of
the trace of the orthogonalized UIJ tensor.
Atom
S1
S2
N4
N5
N3
N2
O2
C15
C16
C7
C19
C21
C20
C12
C17
C18
N1
C5
C22
N6
C4
C13
C14
C6
C9
C8
C3
C11
C2
C1
C10
C25
C26
O1
C24
C23

x
1559.0(6)
5373.9(7)
-1219.6(19)
-3062(2)
-3701(2)
644(2)
3754(2)
-2621(2)
-2022(2)
1469(2)
-70(2)
-643(2)
326(2)
-777(2)
-2427(2)
-1468(3)
5720(2)
2998(2)
984(3)
1832(3)
2973(2)
-1771(2)
-3209(2)
2287(2)
2229(3)
1459(2)
3746(3)
2501(3)
4332(3)
5100(3)
640(3)
5041(3)
5815(4)
591.6(19)
2677(3)
179(3)

y
-3482.0(4)
-2653.0(5)
-1927.4(13)
-749.5(14)
-849.7(14)
-3029.4(14)
-2875.0(16)
-1202.6(15)
-629.9(16)
-3674.6(16)
-229.3(17)
-1439.8(16)
-1232.8(17)
-2285.6(16)
369.4(17)
569.7(17)
-6798.3(17)
-3805.1(18)
24.4(18)
263.6(18)
-5001.0(18)
-1921.7(17)
-1230.1(17)
-3131.2(17)
-5522.1(17)
-4873.8(17)
-5738.7(18)
-1882.9(18)
-5362.8(18)
-6169.5(19)
-5458.8(19)
-1881(2)
-1472(3)
-3814.0(14)
-4809(2)
-3171(2)

z
9649.8(3)
11209.0(4)
15538.4(11)
14375.7(12)
16012.6(12)
16709.7(11)
11607.9(13)
15350.4(13)
13571.5(13)
16012.2(13)
11923.3(14)
13448.1(14)
12632.8(14)
16490.5(13)
12840.7(14)
12026.4(14)
12013.7(14)
14537.8(14)
11109.6(15)
10469.9(14)
14664.1(14)
17252.9(14)
16965.1(14)
15214.9(14)
15490.3(15)
16167.2(14)
13978.6(15)
15119.2(15)
13099.7(16)
12504.5(15)
17048.1(16)
9975.6(18)
11738(2)
8864.9(10)
10302.6(19)
10604.5(17)

U(eq)
20.58(14)
31.54(16)
14.9(3)
17.1(3)
18.3(3)
16.8(3)
37.2(4)
15.1(4)
15.7(4)
15.8(4)
18.6(4)
17.3(4)
19.1(4)
14.9(4)
18.4(4)
19.8(4)
30.0(4)
19.2(4)
23.1(4)
32.0(4)
20.1(4)
18.5(4)
19.1(4)
17.3(4)
21.4(4)
19.7(4)
21.9(4)
22.8(4)
23.8(4)
24.6(4)
27.5(5)
34.0(5)
45.4(7)
27.6(3)
33.3(5)
31.8(5)
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Table 2.4 Anisotropic Displacement Parameters (Å2×103) for Rilpivirine.
The Anisotropic displacement factor exponent takes the form: 2π2[h2a*2U11+2hka*b*U12+…].
Atom
S1

U11
23.6(3)

U22
22.0(2)

U33
16.0(2)

S2
N4
N5
N3
N2
O2
C15
C16
C7
C19
C21
C20
C12
C17
C18
N1
C5
C22
N6
C4
C13
C14
C6
C9
C8
C3
C11
C2
C1
C10
C25

33.0(3)
15.1(8)
12.7(8)
15.9(8)
17.2(8)
42.5(11)
16.6(9)
15.6(9)
12.6(9)
19.5(10)
19.4(10)
19.8(10)
14.1(9)
18.4(10)
22.6(10)
31.5(11)
14.9(10)
23.2(11)
31.3(11)
16.7(10)
19.4(10)
17.3(10)
13.5(9)
22.6(11)
19.4(10)
21.7(11)
23.7(11)
25.5(11)
23.6(11)
35.1(13)
32.0(13)

25.7(3)
14.7(7)
20.8(8)
20.6(8)
19.6(8)
36.3(9)
13.7(8)
17.1(9)
19.2(9)
21.7(9)
15.9(8)
19.7(9)
14.9(8)
17.1(9)
18.0(9)
32.1(10)
25.2(10)
23.9(10)
36.5(11)
24.2(10)
22.3(9)
23.1(9)
20.2(9)
18.2(9)
20.5(9)
20.4(9)
21.9(10)
20.7(10)
28(1)
22.3(10)
41.4(13)

36.4(3)
14.0(7)
14.7(7)
16.5(8)
11.9(7)
33.8(9)
14.9(8)
14.7(8)
14.0(8)
15.5(9)
16.0(9)
17.3(9)
15.9(8)
18.3(9)
17.4(9)
25.2(9)
16.5(9)
21.8(10)
26.4(10)
19.0(9)
13.1(8)
15.8(9)
17.1(9)
23.4(10)
18.1(9)
23.2(10)
23.6(10)
23.3(10)
19.9(9)
25.6(11)
31.6(12)

C26

52.2(18)

54.2(17)

40.4(14)

O1
C24

28.5(9)
32.4(13)

38.1(9)
27.5(11)

16.0(7)
37.8(13)

U23

U13
U12
- 1.87(18)
0.61(17)
6.28(19)
-7.2(2)
-4.6(2)
-3.9(2)
-2.1(6)
1.2(6)
0.0(6)
-0.5(6)
0.6(6)
2.4(6)
-2.4(6)
2.2(6)
1.4(6)
-3.7(6)
-0.3(6)
2.6(6)
3.3(7)
-3.0(7) -19.3(8)
-1.7(6)
0.3(7)
-3.5(7)
-3.7(7)
0.5(7)
-3.1(7)
-4.6(7)
-0.5(7)
3.2(7)
-3.7(7)
1.9(7)
-5.8(8)
-2.8(7)
0.3(7)
-1.2(7)
-5.1(7)
1.7(7)
-0.6(8)
-2.8(7)
0.5(7)
-2.5(7)
-2.1(7)
-0.1(7)
-0.5(7)
1.1(7)
-1.9(7)
-4.1(8)
-8.8(8)
7.5(8)
1.6(8)
-3.0(7)
2.0(7)
-1.8(8)
-2.8(8)
1.3(8)
-4.0(8)
-0.1(8)
9.2(8)
-7.5(9)
-6.7(8)
-0.5(7)
0.8(8)
-3.7(7)
1.7(7)
-1.4(8)
-4.9(7)
3.6(7)
0.4(8)
-2.5(7)
-1.5(7)
-0.3(7)
-6.0(8)
0.4(8)
-1.0(8)
-3.2(7)
-0.7(7)
-1.1(8)
-5.5(8)
1.9(8)
-1.5(8)
-4.3(8)
2.7(8)
-5.7(8)
-3.9(8)
1.1(8)
1.3(8)
-3.0(8)
0.4(8)
0.4(9)
-3.5(8)
7.0(9)
-7.4(9)
-7.7(10) 3.5(10)
14.1(11)
- -0.3(12)
20.4(13)
26.1(14)
-1.1(6)
-3.5(6)
-8.4(7)
-4.9(10)
- 1.2(10)
11.5(10)
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C23

33.2(13)

37.0(12)

25.5(11)

-7.4(9)

6.2(9)

-5.4(10)
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Table 2.5 Bond Lengths for Rilpivirine.
Atom
S1
S1
S1
S2
S2
S2
N4
N4
N5
N5
N3
N3
N2
N2
C16
C16
C7
C7

Atom Length/Å
O1
1.5070(15)
C24
1.784(2)
C23
1.784(2)
O2
1.5083(19)
C25
1.779(3)
C26
1.782(3)
C15
1.333(3)
C12
1.340(2)
C15
1.383(2)
C16
1.402(2)
C15
1.345(3)
C14
1.353(3)
C7
1.430(2)
C12
1.361(2)
C21
1.402(3)
C17
1.406(3)
C6
1.403(3)
C8
1.401(3)

Atom
C19
C19
C19
C21
C12
C17
N1
C5
C5
C22
C4
C4
C13
C6
C9
C8
C3
C2

Atom Length/Å
C20
1.392(3)
C18
1.400(3)
C22
1.438(3)
C20
1.387(3)
C13
1.412(3)
C18
1.380(3)
C1
1.148(3)
C4
1.401(3)
C6
1.395(3)
N6
1.150(3)
C9
1.387(3)
C3
1.468(3)
C14
1.361(3)
C11
1.504(3)
C8
1.393(3)
C10
1.503(3)
C2
1.329(3)
C1
1.432(3)
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Table 2.6 Bond Angles for Rilpivirine.
Atom
O1
O1
C24
O2
O2
C25
C15
C15
C15
C12
N4
N4
N3
N5
N5
C21
C6
C8
C8
C20
C20
C18
C20

Atom
S1
S1
S1
S2
S2
S2
N4
N5
N3
N2
C15
C15
C15
C16
C16
C16
C7
C7
C7
C19
C19
C19
C21

Atom
C24
C23
C23
C25
C26
C26
C12
C16
C14
C7
N5
N3
N5
C21
C17
C17
N2
N2
C6
C18
C22
C22
C16

Angle/˚
106.13(10)
106.18(11)
97.70(12)
107.06(11)
105.76(13)
96.91(13)
116.86(16)
126.50(17)
113.97(17)
122.57(15)
118.45(17)
127.17(17)
114.39(17)
124.50(17)
116.61(17)
118.88(17)
121.21(17)
117.50(17)
121.27(17)
119.81(18)
120.63(19)
119.49(18)
120.15(18)

Atom
C21
N4
N4
N2
C18
C17
C6
N6
C5
C9
C9
C14
N3
C7
C5
C5
C4
C7
C9
C9
C2
C3
N1

Atom
C20
C12
C12
C12
C17
C18
C5
C22
C4
C4
C4
C13
C14
C6
C6
C6
C9
C8
C8
C8
C3
C2
C1

Atom
C19
N2
C13
C13
C16
C19
C4
C19
C3
C5
C3
C12
C13
C11
C7
C11
C8
C10
C7
C10
C4
C1
C2

Angle/˚
120.47(19)
118.44(16)
121.09(17)
120.46(17)
120.86(18)
119.80(18)
121.72(18)
177.6(2)
123.00(18)
118.69(18)
118.27(18)
116.28(17)
124.42(18)
121.70(17)
117.98(17)
120.19(18)
121.39(19)
120.97(18)
118.79(18)
120.24(18)
125.72(19)
120.7(2)
178.7(2)
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Table 2.7 Torsion Angles for Rilpivirine
A
N4
N5

B
C
D
C12 C13 C14
C16 C21 C20

C15 N3
C16 N5
C16 N5

C14 C13
C15 N4
C15 N3

Angle/˚
2.3(3)
178.94(18)
179.31(17)
176.98(17)
7.2(3)
178.94(18)
-1.3(3)
176.44(18)
179.76(16)
1.0(3)
37.9(3)
143.15(19)
-0.9(3)
-23.4(3)
156.94(18)

N5
N2

C16 C17 C18
C7 C6 C5

N2
N2
N2
N2

C7
C7
C7
C12

C6
C8
C8
C13

C11
C9
C10
C14

C15
C15
C15
C15

N4
N4
N5
N5

C12
C12
C16
C16

N2
C13
C21
C17

C16
C16
C7
C7

C20
C18
C12
C12

C19
C19
N4
C13

-0.9(3)
0.0(3)
-16.7(3)
162.12(18)

C6
C6
C6
C6

C7
C7
C5
C5

C8
C8
C4
C4

C9
C10
C9
C3

C21 C16 C17 C18
C20 C19 C18 C17
C12 N4 C15 N5

-1.6(3)
1.3(3)
175.45(16)

C9
C8
C8

C4
C7
C7

C3
C6
C6

C2
C5
C11

C3

C4

C9

C8

C21
C17
N2
N2

C12 N4

C15 N3

-4.9(3)

C12 N2

C7

73.5(2)

C6

A
B
C
D
C12 N2 C7 C8
C12 C13 C14 N3

C4 C3
C14 N3
C14 N3

C2 C1
C15 N4
C15 N5

C17 C16 C21 C20
C18 C19 C20 C21
C5
C5
C22
C22

C4
C4
C19
C19

C9
C3
C20
C18

C8
C2
C21
C17

C4
C4
C4
C4

C5
C5
C9
C9

C6
C6
C8
C8

C7
C11
C7
C10

Angle/˚
-107.8(2)
-2.4(3)
2.1(3)
-0.8(3)
2.6(3)
-10.8(3)
176.09(18)
175.67(18)
-3.0(3)
172.94(19)
-1.2(3)
179.1(2)
178.4(2)
4.9(3)
175.51(16)
-2.4(3)
177.31(19)
-0.5(3)
178.40(19)
171.2(2)
4.4(3)
171.40(19)
179.36(19)
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Table 2.8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement
Parameters (Å2×103) for Rilpivirine.
Atom
H5
H2
H21
H20
H17
H18
H5A
H13
H14
H9
H3
H11A
H11B
H11C
H2A
H10A
H10B
H10C
H25A
H25B
H25C
H26A
H26B
H26C
H24A
H24B
H24C
H23A
H23B
H23C

x

y
-4099
1072
-372
1268
-3375
-1754
3513
-1453
-3916
2246
3835
1445
3016
3182
4240
1137
758
-508
4150
4767
6022
5984
4910
6794
1936
3259
3452
-589
776
-407

z
-512
-3117
-2132
-1780
914
1248
-3444
-2147
-999
-6338
-6556
-1388
-1644
-1802
-4550
-5347
-6293
-5118
-1226
-2404
-1587
-1722
-821
-1223
-5345
-4649
-5162
-2459
-3063
-3821

U(eq)
14248
17304
13924
12558
12908
11537
13976
17929
17467
15597
14181
15140
14489
15666
12864
17656
17035
17028
9961
9551
9735
12453
11610
11442
10549
10861
9857
10362
11178
10798

20
20
21
23
22
24
23
22
23
26
26
34
34
34
29
41
41
41
51
51
51
68
68
68
50
50
50
48
48
48
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CHAPTER 3. CELL BASED STUDIES OF RPV-NC

3.1

Introduction
To track AIE nanocrystals of RPV in vivo, it is essential to first assess the

presence of RPV-NC in vitro. Macrophages have been known to be a key target
of HIV as well as serve as reservoirs and vehicles for HIV dissemination122-124.
They also play an important role in the regulation of disease function during the
disease state125, 126. Furthermore, macrophages are known for their phagocytic
ability to engulf a wide variety of materials such as foreign particles, infected T
cells, virus particles and nanoparticles127. Interactions of nanoparticles with the
macrophage have resulted in the induction of a broad range of activation proteins
that can enhance phagocytosis, secretory function and cell migration, thus
enhancing drug loading while facilitating drug transportation and formation of drug
tissue depots128. Hence, an in vitro assessment of RPV-NC uptake in monocytederived macrophages (MDM) is required and was analyzed herein, using HPLC
for quantitative drug assessments as well as flow cytometry to assess the integrity
of RPV-NC. In addition to macrophages, CD4+ T cells also play an important role
in the pathogenies of HIV infection. Apart from being the major target of HIV
invasion, CD4+ T cells are also the predominant viral reservoirs105, 106. Hence,
assessment of nanoparticle uptake in these cells is of prime importance. Similar to
macrophages, RPV-NC uptake in CD4+ T cells was also assessed by HPLC and
flow cytometry. Monocyte-macrophage and CD4+ T cell activities may differ in
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pure versus combined cell cultures

129

, thus, RPV-NC uptake in isolate or co-

cultures was also studied.
Additionally, HIV utilizes macrophage bridging conduits (BC) or tunneling
nanotubes (TNTs), more commonly referred to as cytoplasmic bridges, that are
formed in infected macrophages to accelerate the intercellular spread of infection
while being shielded from the immune system130, 131. Hence, the presence of RPVNC in these BC or TNTs was observed by confocal microscopy. These studies
demonstrated the presence and uptake of RPV-NC in macrophages and CD4+ T
cells with fluorescence dependent on RPV concentration, indicating and
confirming the integrity of RPV-NC.

50
3.2

Methods

3.2.1 Reagents
Heat-inactivated pooled human serum was purchased from Innovative
Biologics, Herndon, VA, USA. Dulbecco’s Modified Eagle Medium (DMEM) was
purchased from Corning Life Sciences (Tewksbury, MA, USA). Bovine serum
albumin (BSA) and Triton X-100 were purchased from Fisher Scientific (Hampton,
NH). Monoclonal mouse HIV-1p24 (Clone Kal-1) and Dako EnVision+ detection
system HRP labeled polymer anti-mouse antibodies were purchased from Agilent
Technologies (Santa Clara, CA, USA). The primary antibodies used in thestudy
were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA): Rab5 (D11) (sc-46692), Rab7 (H-50) (sc-10767), and Rab14 (sc-98610) (H-55). The Alexa
FlourTM secondary antibodies were purchased from Thermo Fischer Scientific
(Waltham, MA, USA): 594 goat anti-rabbit (A11037), 594 goat anti-mouse
(A11005), 488 chicken anti-mouse (A21200), and 488 goat anti-rabbit (A11008).
Human peripheral blood monocytes were obtained by leukapheresis from
HIV-1, 2 and hepatitis B seronegative donors and purified by countercurrent
centrifugal elutriation. Monocyte-derived macrophages (MDM) were cultured in
DMEM supplemented with 10% heat-inactivated pooled human serum, 10 μg/ml
ciprofloxacin, 50 μg/ml gentamicin, and 1,000 U/ml equivalents of macrophage
colony-stimulating factor for 7 days to promote monocyte-macrophage
differentiation (MDM) 132, 133. The following reagent was obtained through the NIH

51
AIDS Reagent Program, Division of AIDS, NIAID, NIH: CEM-SS cells (CD4+ T
cells) from Dr. Peter L. Nara 134, 135.

3.2.2 Cellular uptake in MDM and T cells
Cell vitality studies for MDM were carried out using 3-(4,5-dimethylthiazol2-yl)-2,5 diphenyltetrazolium bromide (MTT)

136

. RPV-NC concentrations from 12

to 200 μM were prepared and added to the cells in triplicate. After treatment for 8
hours, the analysis was carried out as described previously

116

. For T cell vitality

studies, CD4+ T cells were treated with 3 to 200 μM of RPV-NC diluted in RPMI
medium containing 10% FBS and 1% penicillin-streptomycin for 24 hours in a 96well round-bottom plate. The supernatant was removed by centrifugation at 650 g
for 5 min and cells were washed twice with PBS. Cells were then stained using
LIVE/DEAD™ Fixable Green Dead Cell Stain Kit (Thermo Fischer Scientific,
Waltham, MA, USA) according to manufacturer’s protocol and fixed in 2%
paraformaldehyde (PFA).
MDM and CD4+ T cell uptake of the particles was assessed by flow
cytometry and UPLC-TUV. Adherent MDM were treated in biological triplicates
with 100 µM RPV-NC for 8 hours and cells were collected at various time points
after washing and scraping into 1 ml PBS. For uptake in lymphocytes, CD4+ T
cells were allowed to attach for one hour in poly-L-lysine coated plates at 37°C 137.
Cells were then treated with appropriate concentrations of RPV-NC and collected
at the aforementioned time points by washing and scraping into 1 ml PBS. Cell
counting was done using an Invitrogen Countess Automated Cell Counter
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(Invitrogen Corp., Carlsbad, CA, USA). Cells were pelleted by centrifugation at 650
g for 8 min at 4°C and lysed in methanol by sonication for 1 min followed by
centrifugation to remove cell debris. Drug concentration in methanol extracts was
analyzed UPLC-TUV as previously reported 96, 111. For analysis by flow cytometry,
MDM and CD4+ T cells were treated similarly, stained with LIVE/DEAD™ Fixable
Green Dead Cell Stain Kit and fixed in 2% PFA. For co-culture experiments,
additional staining was performed using mouse anti-human CD4 and CD14
antibodies according to the manufacturer’s protocol.

3.2.3 Antiretroviral activities
Antiretroviral activities of RPV-NC and native RPV were evaluated by
measures of HIV reverse transcriptase (RT) activity and HIV-p24 staining, as
previously described,138 with some modifications. In brief, MDM were treated with
100 µM RPV and RPV-NC for 8 hours. Treatment media was then replaced with
fresh media. On days 1, 5, 10 and 15 post-treatment, MDM were challenged with
HIV-1 ADA for 16 hours at a multiplicity of infection (MOI) of 0.1 infectious virions
per cell. MDM were allowed to stay in culture for 10 days after infection with half
media exchanges every 2 days and a full media exchange on day 8. Culture
supernatants were then collected and analyzed for progeny virion production by
RT activity 139. At the same time, cells were washed with PBS and fixed in 4% PFA
for 15 min for HIV-p24 staining 8. Images were analyzed using a Nikon TE300
microscope with a 20x magnification objective.
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3.2.4 Transmission electron microscopy and atomic force microscopy
For TEM tests, MDM and CD4+ T cells were incubated in 12-well plates at
106 cells/well for 8 hours with RPV-NC (100 µM). Cells were washed 2x with PBS
and centrifuged at 650 g for 8 min at 4°C after treatment and cell pellets were
suspended in a solution of 2% glutaraldehyde and 2% PFA in 0.1 M Sorenson’s
phosphate buffer (pH 6.2) for a minimum of 24 hours at 4°C. TEM analysis was
then carried out as previously described

96, 115

. For TEM analysis, fixed samples

were washed three times with PBS to clear excess fixative. During processing,
samples were post-fixed in a 1% aqueous solution of osmium tetroxide for 30 min.
Subsequently, samples were dehydrated in a graded ethanol series (50, 70, 90,
95, and 100%) and propylene oxide was used as a transition solvent between the
ethanol and araldite resin. Samples were allowed to sit overnight in a 50:50
propylene oxide: resin solution until all the propylene oxide had evaporated.
Samples were then incubated in fresh resin for 2 hours at room temperature before
the final embedding. Polymerization took place at 65°C for 24 hours. The staining
procedure was as follows: 10 min in 2% uranyl acetate, washed three times in
distilled water, 10 min in Reynolds Lead Citrate, washed three times in distilled
water. Thin sections (100 nm) made with Leica UC6 Ultracut ultramicrotome were
placed on 200 mesh copper grids and examined on the Tecnai G2 Spirit TWIN
(FEI, Hillsboro, OR, USA) operating at 80 kV. Images were acquired digitally with
an AMT digital imaging system.
For AFM analysis, MDM were treated with RPV-NC at 100 µM for 8 hours,
washed and fixed in 4% PFA. Coverslips with fixed cells were removed from wells
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and mounted on a slide for AFM analysis. Images were acquired in the air using
an MFP-3D™ system (Asylum Research, Santa Barbara, CA, USA) operating in
tapping mode. AFM probes MSNL-F with a nominal spring constant ∼0.6 N/m were
used for imaging. Image processing was performed using Femtoscan software
(Advanced Technologies Center, Moscow, Russia).

3.2.5 Immunocytochemistry and confocal microscopy
Subcellular immunocytochemistry localization of RPV-NC treated MDM and
T cells and immunocytochemistry staining were performed as previously described
with some modifications

131, 140, 141

. Briefly, after MDM were treated with RPV-NC

(100 µM), cells were washed with PBS and fixed with ice-cold 4% PFA and rinsed
three times with PBS. MDM were then treated with 0.5% v/v Triton-X-100 for
15 min to permeabilize the cells and again washed with PBS. A mixture of 5% w/v
bovine serum albumin (BSA) in PBS and 0.1% v/v Triton-X-100 was used as a
blocking solution for 1 hour, and 50 mM NH4Cl was used as a quenching solution
for 15 min and washed once with 0.1% Triton-X-100 in PBS. MDM were next
treated with primary antibodies against Rab5 for early endosomes, Rab7 for late
endosomes, or Rab14 for recycling endosomes. Primary antibodies were diluted
1:25 (v/v: antibody: blocking solution) and incubated overnight with shaking at 4°C
as previously described

115

. MDM were then treated with secondary antibody in

blocking solution (1:50) for 2 hours at room temperature. F-actin was stained using
Alexa Fluor™ 488 Phalloidin (Thermo-Fischer Scientific, Waltham, MA, USA)
according to the manufacturer’s protocol. Nuclei were stained using NucRed™
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Live 647 ReadyProbes™ Reagent (Thermo-Fischer Scientific, Waltham, MA,
USA). Cells were imaged using a 63x oil objective on an LSM 710 confocal
microscope (Carl Zeiss Microimaging, Inc., Dublin, CA, USA). Zeiss LSM 710
Image browser AIM software version 4.2 was used to determine the number of
pixels and the mean intensity of each channel.

3.2.6 UPLC-MS/MS analysis of RPV
For analysis of RPV in plasma, 10 µL of internal standard (IS) solution (250
ng/ml indinavir and 500 ng/ml lopinavir; final concentration 25 ng/ml indinavir, 50
ng/ml lopinavir) was added to 25 µl of plasma along with 1 ml of ice-cold Optimagrade acetonitrile. Samples were then vortexed and centrifuged at 17,000 g for 10
min at 4°C. Supernatants were evaporated using a Thermo Scientific Savant
Speed Vacuum (Waltham, MA, USA) and reconstituted in 100 µL 50% (v/v)
optima-grade methanol in optima-grade water. Standard curves were prepared in
blank rat plasma in the range of 0.2–2000 ng/ml RPV with 10 µL of IS added. For
tissue analyses, 100 mg of tissue was homogenized in 4 volumes of 90% (v/v)
Optima-grade methanol/water using a Qiagen Tissue Lyzer II (Valencia, CA, USA).
To 100 µL of tissue homogenate, 80 µL of 100% Optima-grade methanol, 10 µL of
50% Optima-grade methanol (v/v) in MS-grade water, and 10 µL IS was added.
Standard curve samples were prepared using equivalent tissue matrix dilutions, to
which 80 µL of Optima-grade methanol, 10 µL of 50% Optima-grade methanol (v/v)
in MS-grade water spiked with standard drug concentrations and 10 µL of IS were
added. Chromatographic separation of 10 µL of plasma or tissue samples was
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achieved with an ACQUITY UPLC BEH Shield RP18 column (1.7 µm, 2.1 mm x
100 mm) using a 7 min gradient of mobile phase A (7.5 mM ammonium
bicarbonate in Optima-grade water adjusted to pH 7 using acetic acid) and mobile
phase B (100% Optima-grade methanol) at a flow rate of 0.25 ml/min. The initial
mobile phase composition of 70% B was held for 4.75 min and was increased to
95% B in 0.25 min then held constant for 0.75 min. Mobile phase B was reset to
70% in 0.25 min and the column was equilibrated for 1.0 min before the next
injection. RPV was detected at a cone voltage of 92 V and collision energy of 56
V. Multiple reaction monitoring (MRM) transitions used for RPV, indinavir and
lopinavir were 367.032 m/z > 127.859 m/z, 614.14 m/z > 97.023 m/z, and 629.177
m/z > 155.031 m/z, respectively. Spectra were analyzed and quantified by
MassLynx software version 4.1 using the ratio of analyte peak area to IS peak
area.

3.2.7 Statistics
For all studies, data were analyzed using GraphPad Prism 7.0 software (La
Jolla, CA) and presented as the mean ± the standard error of the mean (SEM).
Experiments were performed using a minimum of three biologically distinct
replicates. Sample sizes were not based on power analyses. For comparisons of
two groups, Student’s t-test (two-tailed) was used. HIV-1 RT activity and HIV-1p24
staining were analyzed by one-way ANOVA with Bonferroni correction for multiple
comparisons. For studies with multiple time points, two-way factorial ANOVA and
Bonferroni’s post-hoc tests for multiple comparisons were performed. Extreme

57
outliers beyond the 99% confidence interval of the mean and 3-fold greater than
the SEM were excluded. Significant differences were determined at P < 0.05.
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3.3

Results

3.3.1 Cell-based RPV-NC activities
To assess the cellular kinetics of RPV-NC, cytotoxicity, particle uptake and
antiretroviral activities are required in HIV-1 infectible macrophages and CD4+ T
cells

142-145

. MDM treated with RPV-NC demonstrated no apparent cytotoxicity at

concentrations up to 200 µM over 8 hours using MTT vitality assays (Figure 3.1
A). To assess cell uptake, MDM were treated with 100 µM RPV-NC and at 2, 4, 6
and 8 hours, media was removed, and cells lysed for drug analysis. Cellular RPV
concentrations increased over time with maximum uptake seen at 6 hours (60
µg/106 cells) (Figure 3.1 B). AFM micrographs of replicate treated MDM showed
no cell surface distortions upon uptake of RPV-NC (Figure 3.1 C). The intracellular
uptake of RPV-NC was confirmed by TEM demonstrating RPV-NC in the
macrophage cytoplasm and in the membrane-bound intracellular structures
(Figure 3.1 D). Because AIE relies on particle aggregation, we studied
nanoparticle integrity in MDM by flow cytometry. Up to 98.8% of MDM
demonstrated nanoparticle uptake at 8 hours (Figure 3.1 E), further highlighting
their ability to phagocytose nanoparticles in large amounts 146, 147. Uptake of RPVNC by CD4+ T cells was similarly evaluated. No cytotoxicity was observed at
concentrations of up to 200 µM when treated for 8 hours (Figure 3.2 A). Cell
uptake was determined at 2, 4, 6 and 8 hours after 100 µM RPV-NC treatments.
Maximum uptake of 8 µg/106 cells was seen at 8 hours (Figure 3.2 B). To assess
RPV-NC integrity over time within CD4+ T cells, the cells were examined by flow
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cytometry. Both the percent and median fluorescent intensity (MFI) increased with
time, corresponding to the efficiency of endocytosis and RPV-NC accumulation
within CD4+ T cells, respectively. The RPV-NC positive population increased from
11% at 2 hours to 30% at 24 hours along with a 10-fold increase in MFI (Figure
3.2 C and D). Pearson correlation between the median fluorescent intensity (MFI)
and drug concentration showed an r-value of 0.8800 when cells were treated with
100 µM RPV-NC over a time course of 24 hours (Figure 3.2 E). Correlative studies
were also performed by varying the treatment concentration with a fixed harvest
after 24 hours. Results revealed that both MFI and intracellular RPV were
positively correlated with treatment concentration and showed a Pearson r-value
of 0.7925 (Figure 3.2 F). TEM images from cells treated for 24 hours with 100 µM
RPV-NC depict the discernible presence of nanoparticles in T cell cytoplasm and
membrane-bound intracellular structures (Figure 3.2 G). Thus, RPV-NC uptake
kinetics in a model for CD4+ T cells can be monitored using AIE.
Monocyte-macrophage and CD4+ T cell activities may differ in pure versus
combined cell cultures 129, thus, we studied RPV-NC uptake in isolate or co-culture
conditions over 24 hours. CD14+ MDM demonstrated greater uptake of RPV-NC
in co-culture with CD4+ T cells (Figure 3.4 A and B, Figure 3.5). In contrast, CD4+
lymphocytes exhibited less efficient endocytosis of RPV-NC in the presence of
macrophages. These differences emphasize the phagocytic potential of
macrophages, which readily outcompete T cells to engulf RPV-NC, whereas
lymphocyte immune activation of macrophages may enhance their uptake
potential

132

. RPV-NC cytoplasmic accumulation in macrophages was further
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detected using flow cytometry of nanocrystal AIE as exhibited by the rightward shift
in histogram peaks with varying treatment concentration (Figure 3.4 C). Pearson
correlation analysis revealed a high positive correlation (r = 0.9810) between MFI
and treatment concentration in macrophages (Figure 3.4 D). In contrast, CD8+ T
cells and CD19+ B lymphocytes exhibited no such dose-dependent accumulation
of RPV-NC (Figure 3.7).

3.3.2 Cellular and sub-cellular colocalizations
To track their fate once inside cells, RPV-NC sub-cellular localization in
monocyte-macrophages and CD4+ T cells was studied by confocal microscopy.
MDM were treated for 8 hours with 100 µM RPV-NC then immune-stained for
endosomal markers that included Rab5 (early endosomes), Rab7 (late
endosomes) and Rab14 (recycling endosomes). Co-localization of RPV-NC was
readily seen in stained endosomal compartments (Figure 3.8 A) with the Rab14
endosomes indicating that RPV-NC can be recycled for release by macrophages
133, 140, 148

. Another potential means of RPV-NC dissemination during HIV-1

infection is through cytoplasmic bridges, also called tunneling nanotubes (TNTs)
or bridging conduits (BC), that facilitate cell-to-cell communication and intracellular
material exchange

130, 140, 149-151

. Accordingly, TNTs of RPV-NC treated, HIV-1

ADA-infected MDM were visualized by f-actin staining. Figure 3.8 B shows the
formation of multinucleated giant cells (i) and cytoplasmic bridges (ii) with RPV-NC
observed in both the infected cells and the cytoplasmic bridges (iii and iv). Because
uptake in CD4+ T cells occurs primarily by endocytosis 152, the extent of uptake is
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lower than in macrophages. To visualize RPV-NC taken up by T cells, CD4+ T
cells treated with RPV-NC were analyzed by confocal microscopy. RPV-NC was
readily seen in the T cell cytoplasm (Figure 3.8 C).
Once RPV-NC entry and intercellular dissemination had been studied,
antiretroviral activities of RPV-NC were also determined in MDM. MDM were
treated with 100 µM RPV-NC for 8 hours followed by replacement with fresh media.
On days 1, 5, 7 and 10 following treatment, cells were infected with HIV-1 ADA at
a MOI of 0.1. 10 days after infection, cell supernatants were analyzed for reverse
transcriptase (RT) activity. Cells were stained for HIV-1 p24 in parallel. Viral
suppression was observed up to day 10 (Figure 3.9). These results indicate that
the antiretroviral efficacy of RPV-NC parallels that of native RPV.
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3.4

Discussion
Uptake of RPV-NC by macrophages and CD4+ T cells was evaluated by

various methods including HPLC, flow cytometry, TEM and AFM. Results confirm
the presence of intact nanocrystals of RPV. Additionally, a positive correlation was
observed between the MFI and drug concentrations over time. Correlative studies
were also performed by varying the treatment concentration over a fixed period of
time. Results revealed that both MFI and intracellular RPV were positively
correlated with treatment concentration.
Studies of RPV-NC uptake in co-cultured MDMs and CD4+ T cells showed
increased amounts of RPV-NC in the macrophages due to their phagocytic activity
as well as due to activation in the presence of lymphocytes132. These results
highlight the preferential sequestration of antiretroviral nanocrystals by HIVinfectable macrophages and to a lesser degree CD4+ T cells, rather than by
lymphocyte subtypes that are resistant to HIV-infection. To this end, AIE
characteristics of RPV-NC facilitate the quantitative assessment of drug uptake in
primary cells under conditions more similar to those encountered in vivo.
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3.5

Figures

64
Figure 3.1 RPV-NC macrophage targeting.
(A) MDM cell vitality was determined by the MTT assay. Data are expressed as a
percent of control absorbance. (B) Uptake of RPV-NC in MDM upon treatment with
100 µM RPV-NC as determined by UPLC-MS. (C) AFM images of control and
RPV-NC treated MDM. (D) TEM images of control and RPV-NC treated MDM
showing internal morphology. The detailed evaluation of membrane-bound
intracellular structures at areas of interest bordered in dotted red lines are
presented in the magnified panels (ii) and (iii) and illustrate RPV-NC within
membrane-bound intracellular structures. (E) Quantitative assessment of RPV-NC
uptake by MDM via flow cytometry. MDM treated with RPV-NC (100 µM) for 8
hours were stained with a live-dead fluorophore and fixed. The percent of live MDM
was determined by selecting the fluorophore dim (live) cells sub-gated from singlecells of the main forward-scatter and side-scatter density plot. The percent of RPVNC and live double-positive cells (bottom panel) were gated based on untreated,
live-stained negative controls (top panel).
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Figure 3.2 RPV-NC detection in CD4+ T cells.
(A) CD4+ T cell vitality assessed by flow cytometry. The percent live population is
based on gating for GFPdim cells. (B) Uptake of RPV-NC in CD4+ T cells upon
treatment with 100 µM RPV-NC for 8 hours as determined by UPLC. (C) Flow
cytometric quantitation of RPV-NC uptake in T cells. CD4+ T cells were treated
with RPV-NC (100 µM) for 2, 4, 6, 12, or 24 hours, then stained with live-dead
indicating fluorophore and fixed. Gating for double-positive live, RPV-NC
containing cells was performed versus untreated control based on the gating
strategy noted above (Figure 3.1E, full gating shown in Figure 3.3). (D) MFI for
RPV-NC positive populations at each time point. (E) Pearson correlation between
MFI and drug concentration; r = 0.8800. (F) MFI and RPV levels in CD4+ T cells
treated with increasing concentrations of RPV-NC. (G) TEM images of control and
RPV-NC treated CD4+ T cells showing internal morphology. The detailed
evaluation of membrane-bound intracellular structures at areas of interest
bordered in dotted red lines are presented in the magnified panels (ii) and (iv) and
illustrate nanoparticles (indicated by arrows) within membrane-bound intracellular
structures.
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Figure 3.3 Gating strategy for RPV-NC uptake in T cells.
Single cells were sub-gated into FITCbright and FITCdim. FITCdim cells were then
gated for RPV-NC positive populations based on untreated control cells.
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Figure 3.4 RPV-NC in macrophage-T cell co-cultures.
(A) Primary MDM and PBL from human blood elutriation were treated in isolation
or co-culture with RPV-NC (100 µM) for 24 hours. Treated and untreated (negative
control) cells were stained with antibody cocktail against CD45 (pan-leukocyte),
CD3 (T cell), CD4, CD8, and CD14 (monocyte-macrophage) epitopes. Sub-gating
from parent populations is depicted in Figure 3.5 and the percent of RPV-NC
containing (bottom plots) CD14+ monocyte-macrophage and CD4+ T cell
populations was determined against negative control (top plots). (B) The percent
of each population containing RPV-NC is represented in heat map format for both
CD14+ monocyte-macrophages and CD4+ T cells treated with a range of
concentrations of RPV-NC (12.5-100 µM), either in isolation or co-culture. (C)
Histogram showing the increasing MFI of RPV-NC positive monocyte-macrophage
populations treated in isolation at various concentrations (12.5-100 µM). (D)
Pearson correlation analysis comparing MFI and RPV-NC treatment concentration
from (C) yielded an r value of 0.9810.
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Figure 3.5 RPV-NC uptake in co-cultured macrophages and CD4+ T cells.
Flow cytometry plots of CD14+ macrophages and CD4+ T cells treated with 12.5,
25, 50 and 100 µM RPV-NC. Gates show cells positive for RPV-NC on UV 450/50.
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Figure 3.6 Gating strategy for RPV-NC uptake in co-cultured cells.
Cells were gated separately into lymphocytes and macrophages. Lymphocytes
were then sub-gated into CD19+ and CD3+ populations. CD3+ populations were
then sub-gated into CD8+ and CD4+ populations. Macrophages were gated into
CD14+ and CD3+ populations. RPV-NC positive CD4+ and CD14+ populations
were then gated based on control untreated cells.
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Figure 3.7 RPV-NC uptake by PBMC lymphocytes.
Human peripheral blood mononuclear cells (PBMC) were treated with RPV-NC at
0-100 uM drug for 24 hours then immunostained to identify HIV non-infectible
CD8+ T (A-B) and CD19+ B (C-D) lymphocytes via flow cytometry. Histograms
showing median fluorescent intensity (MFI) corresponding to RPV-NC intracellular
accumulation among lymphocyte subtypes are plotted (A-C). Pearson correlation
analyses of MFI against treatment concentration were performed (C-D) and shown
by two-tailed p-value to be not significant at α = 0.05 among each of the
lymphocyte subtypes.
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Figure 3.8 Cellular and sub-cellular RPV-NC localizations.
(A) Representative images of macrophages treated with RPV-NC (pseudo-colored
red) and Alexa-Fluor 488 secondary antibody against primary Rab5, Rab7 or
Rab14 antibodies (green). Yellow areas (merged images) indicate co-localization
of RPV-NC with endosomal compartments. Nuclei are stained with NucRed
(pseudo-colored blue). (B) Cellular distribution of RPV-NC (blue) in infected
macrophages. Virus particles were visualized by staining with Alexa-Fluor 594
secondary antibody against p24 primary (red). Cell cytoskeleton and tunneling
nanotubes were visualized by staining for F-actin (green). (i) Control macrophages
showing giant cell formation upon infection. (ii) and (iii) Infected macrophages
showing the formation of tunneling nanotubes (indicated by the white arrows) and
the presence of RPV-NC in the cell cytoplasm. (iv) Presence of RPV-NC in the
tunneling nanotubes of infected macrophages (indicated by the arrows). Nuclei are
stained with NucRed (pseudo-colored white). (C) Presence of RPV-NC (pseudocolored red) in CD4+ T cells. Nuclei are stained with NucRed (pseudo-colored
blue).
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Figure 3.9 Antiretroviral activity of RPV-NC in MDM.
(A) Progeny HIV virion production was determined by HIV reverse transcriptase
(RT) activity using beta scintillation spectroscopy. (B) HIV p24 staining (brown)
counterstained with hematoxylin (blue) (scalebar = 200 μm).
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CHAPTER 4. PHARMACOKINETIC (PK) AND
BIODISTRIBUTION ASSAYS
4.1

Introduction
Animal models are vital aspects of the research world and have been widely

used to advance scientific findings and predict clinical outcomes. While no single
animal model can completely recapitulate human disease, significant progress has
been made in advancing animal models to closely mimic human systems. Animal
models enable us to make important predictions about drug pharmacokinetics for
possible use in humans. Key insights can be obtained on disease progression and
pathogenesis, as well as drug biodistribution and pharmacokinetics. In the current
study, the tissue pharmacokinetics and biodistribution of RPV-NC were evaluated
in Sprague-Dawley rats as well as human peripheral blood lymphocyte (PBL)reconstituted mice. A short 5-day PK study was carried out in Sprague-Dawley rats
while a longer 10-day PK profile was studied in PBL-reconstituted mice. Animal
tissues were also analyzed for the presence of intact nanoparticles by confocal
microscopy.
Finally, to track nanoparticles in CD4+ T cells and monocyte-macrophages,
a second murine model, the human CD34+ hematopoietic stem cell (HSC)reconstituted model, was employed to assess uptake of RPV-NC in human
immune cells153. Single cell isolates from liver and spleen tissue were subjected to
fluorescence-activated cell sorting (FACS) to detect RPV-NC CD4+ and CD14+
cell populations that are known cellular reservoirs of HIV154. Our data provide
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evidence that AIE can be used as a platform to detect ARV delivery to cellular
reservoirs of HIV.
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4.2

Methods

4.2.1 Reagents
FITC mouse anti-human CD45, BUV805 mouse anti-human CD3, APC
mouse anti-human CD4, PE mouse anti-human CD14, BV605 mouse anti-human
CD19 and BV421 mouse anti-human CD8 were purchased from BD Biosciences
(San Jose, CA, USA). Methanol, hexane and optima-grade solvents were
purchased from Thermo Fischer Scientific. Bovine serum albumin (BSA), Gibco
RPMI Medium 1640 and HyClone™ Penicillin Streptomycin 100x solution were
purchased from Thermo Fischer Scientific. Fetal bovine serum (FBS) was
purchased from Atlanta Biologicals (Flowery Branch, GA, USA).

4.2.2 In vivo pharmacokinetic (PK) and biodistribution assays
PK and biodistribution studies for RPV-NC were carried out in rats and mice.
For the first study, Sprague-Dawley rats (180-200 g, Jackson Labs, Bar Harbor,
ME, USA) were injected IV with 45 mg/kg RPV-NC. On days 1 and 2 post-injection
blood was collected. Plasma was subsequently isolated by centrifugation at 2000
g for 5 min for drug quantification tests by UPLC-MS/MS. Five days after injection
the animals were sacrificed, and tissues (liver, spleen and lymph node) were
stored. In a replicate study, male 6- to 8-week-old NOD/SCID/IL2Rgc-/- (NSG) mice
(Jackson Labs, Bar Harbor, ME, USA) were injected intraperitoneally with 25x106
human peripheral blood lymphocytes (PBL). These cells were obtained by
leukapheresis and centrifugal elutriation and used to reconstitute the NSG mice.
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Twelve days after reconstitution, mice were injected intravenously with 45 mg/kg
RPV-NC. After 10 days, the animals were sacrificed and tissues were collected for
drug quantification by LC-MS/MS

96, 111

. For confocal analysis, 5 µm sections of

paraffin-embedded tissue were fixed on glass slides and stained with appropriate
antibodies. For rats, spleen tissue sections were probed with rabbit anti-rat
polyclonal antibody to ionized calcium-binding adaptor molecule-1 (Iba-1) (1:500,
Wako Chemicals, Richmond, VA, USA) to detect macrophages

115

. Primary

antibody was detected with anti-rabbit secondary antibody conjugated to Alexa
Fluor 488 (Thermo-Fischer Scientific, Waltham, MA, USA). For PBL mice, spleen
and lymph node tissue sections were stained with CD4 Monoclonal Antibody
(OKT4 (OKT-4)), Alexa Fluor 488. NucRed™ Live 647 ReadyProbes™ Reagent
(Thermo-Fischer Scientific, Waltham, MA, USA) was used as a nuclear stain.

4.2.3 Toxicological assessments
In-vivo toxicity of RPV-NC was assessed by serum chemistry and
histological examination. For histological examination, 5 μm sections of paraffinembedded tissues were affixed to glass slides and stained with hematoxylin and
eosin. Images were captured with a 20x objective using a Nuance EX multispectral
imaging system affixed to a Nikon Eclipse E800 microscope (Nikon Instruments,
Melville, NY, USA). Histopathological assessment was conducted in accordance
with the guidelines of the Society of Toxicologic Pathology. For serum chemistry
analysis, rat blood samples were collected before and five days after RPV-NC
administration. Albumin (ALB), alkaline phosphatase (ALP), total bilirubin (TBIL),
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blood urea nitrogen (BUN), total protein (TP) and creatinine (CRE) were
quantitated using a VetScan comprehensive diagnostic profile disc and a VetScan
VS-2 instrument (Abaxis Veterinary Diagnostics, Union City, CA, USA).

4.2.4 Nanoparticle tracking in humanized mice
Nanoparticle tracking in CD4+ T cells and macrophages was assessed in
humanized mice. NSG mice were reconstituted at birth with CD34+ HSC isolated
from umbilical cord blood

155

. Reconstituted mice, six-to-eight weeks old, were

injected IV with 45 mg/kg of RPV-NC. At 24 hours following particle injection, mice
were sacrificed, and the liver and the spleen were collected. Liver and spleen
tissue were passed through a 70 µm cell strainer to obtain single cell suspensions.
For flow cytometry analysis, cell suspensions were stained with antibodies to
human CD45, CD14, CD4, CD8 and CD3 as per the manufacturer’s protocol and
fixed in 2% PFA. For drug quantification, single cell suspensions from the liver and
spleen tissue were stained with antibodies to human CD45, CD3, CD4 and CD14
antibodies and subjected to FACS on BD FACS Aria II (BD Biosciences, San Jose,
CA, USA). Sorted cells were pelleted by centrifugation at 700 g for 5 min at 4°C
and analyzed by UPLC-MS/MS as described below.

4.2.5 UPLC-MS/MS analysis of RPV
For analysis of RPV in plasma, 10 µL of internal standard (IS) solution (250
ng/ml indinavir and 500 ng/ml lopinavir; final concentration 25 ng/ml indinavir, 50
ng/ml lopinavir) was added to 25 µl of plasma along with 1 ml of ice-cold Optima-
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grade acetonitrile. Samples were then vortexed and centrifuged at 17,000 g for 10
min at 4°C. Supernatants were evaporated using a Thermo Scientific Savant
Speed Vacuum (Waltham, MA, USA) and reconstituted in 100 µL 50% (v/v)
optima-grade methanol in optima-grade water. Standard curves were prepared in
blank rat plasma in the range of 0.2–2000 ng/ml RPV with 10 µL of IS added. For
tissue analyses, 100 mg of tissue was homogenized in 4 volumes of 90% (v/v)
Optima-grade methanol/water using a Qiagen Tissue Lyzer II (Valencia, CA, USA).
To 100 µL of tissue homogenate, 80 µL of 100% Optima-grade methanol, 10 µL of
50% Optima-grade methanol (v/v) in MS-grade water, and 10 µL IS was added.
Standard curve samples were prepared using equivalent tissue matrix dilutions, to
which 80 µL of Optima-grade methanol, 10 µL of 50% Optima-grade methanol (v/v)
in MS-grade water spiked with standard drug concentrations and 10 µL of IS were
added. Chromatographic separation of 10 µL of plasma or tissue samples was
achieved with an ACQUITY UPLC BEH Shield RP18 column (1.7 µm, 2.1 mm x
100 mm) using a 7 min gradient of mobile phase A (7.5 mM ammonium
bicarbonate in Optima-grade water adjusted to pH 7 using acetic acid) and mobile
phase B (100% Optima-grade methanol) at a flow rate of 0.25 ml/min. The initial
mobile phase composition of 70% B was held for 4.75 min and was increased to
95% B in 0.25 min then held constant for 0.75 min. Mobile phase B was reset to
70% in 0.25 min and the column was equilibrated for 1.0 min before the next
injection. RPV was detected at a cone voltage of 92 V and collision energy of 56
V. Multiple reaction monitoring (MRM) transitions used for RPV, indinavir and
lopinavir were 367.032 m/z > 127.859 m/z, 614.14 m/z > 97.023 m/z, and 629.177
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m/z > 155.031 m/z, respectively. Spectra were analyzed and quantified by
MassLynx software version 4.1 using the ratio of analyte peak area to IS peak
area.

4.2.6 Statistical analyses
For all studies, data were analyzed using GraphPad Prism 7.0 software (La
Jolla, CA) and presented as the mean ± the standard error of the mean (SEM).
Sample sizes were not based on power analyses. For comparisons of two groups,
Student’s t-test (two-tailed) was used. Tissue drug levels and T cell populations
were analyzed by one-way ANOVA with Bonferroni correction for multiple
comparisons. For studies with multiple time points, two-way factorial ANOVA and
Bonferroni’s post-hoc tests for multiple comparisons were performed. Animal
studies included a minimum of six animals per group unless otherwise noted.
Extreme outliers beyond the 99% confidence interval of the mean and 3-fold
greater than the SEM were excluded. Significant differences were determined at
P < 0.05.

4.2.7 Study approval
All experimental protocols involving the use of laboratory animals were
approved by the UNMC Institutional Animal Care and Use Committee (IACUC)
ensuring the ethical care and use of laboratory animals in experimental research.
All animal studies were performed in compliance with UNMC institutional policies
and NIH guidelines for laboratory animal housing and care. Human blood cells
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were isolated by leukapheresis from HIV-1/2 and hepatitis seronegative donors
and were deemed exempt from approval by the Institutional Review Board (IRB)
of UNMC. Human CD34+ hematopoietic stem cells were isolated from umbilical
cord blood and are exempt from UNMC IRB approval.
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4.3

Results

4.3.1 Pharmacokinetics (PK) and biodistribution
To correlate RPV-NC in vitro cellular uptake with tissue and cellular uptake
in vivo, biodistribution and PK profiles of RPV-NC were assessed in rats and
humanized mice. Figure 4.1 A shows a schematic outlining the time course of the
studies in the indicated animal models. A short-term biodistribution and PK
analysis was carried out in Sprague-Dawley rats injected intravenously (IV) with
45 mg/kg RPV equivalent of RPV-NC. On days 1, 2 and 5 post-injection, blood
samples were collected, and plasma was analyzed by UPLC-MS/MS for drug
quantification. Animal tissues were collected on day 5 post-injection and the drug
was quantified by UPLC-MS/MS. Figure 4.1 B shows plasma drug levels over time
as well as day 5 liver, spleen and lymph node drug levels. As shown in Figure 4.1
B (i), plasma drug levels decreased from 134.5 ± 15.3 ng/ml on day 1 to 1.5 ± 0.2
ng/ml on day 5. In tissues, drug levels were highest in the liver (3540 ng/g of
tissue), followed by the spleen (94.5 ng/g of tissue) and the lymph nodes (9.5 ng/g
of tissue) in Figure 4.1 B (ii). The rapid decline of plasma drug levels and
increased accumulation in the tissues indicates that RPV-NC can form tissue
depots. Similar results were seen with a polymeric nanoformulation of RPV where
drug levels were found to be highest in the liver, spleen and lymph node tissues116.
Toxicological assessments of liver and spleen tissues from rats treated with
RPV-NC showed no histological abnormalities when compared to tissues from
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untreated controls. Also, no biochemical or hematological effects of RPV-NC were
seen in treated animals (Figure 4.2).
To track RPV-NC biodistribution in human immune cells, we adoptively
transferred human peripheral blood lymphocytes (PBL) into NSG mice and dosed
animals with 45 mg/kg drug. Tissues were collected on day 10 post-injection and
RPV concentration was determined. Analysis of RPV drug levels in excised tissue
showed the highest drug levels in the liver as seen in Figure 4.1 B(iii). Having
observed measurable quantities of RPV in tissues, we searched for intact
nanoparticles displaying AIE in HIV-1 infectible cells. Confocal imaging of rat
spleens revealed discernable overlap between UV-excitable RPV-NC and Iba-1+
rat macrophages (Figure 4.1 C). This finding extended to human CD4+ leukocytes
in PBL-reconstituted mice (Figure 4.1 D, E and F). A high percentage of human
CD4+ splenocytes exhibited RPV-NC-associated fluorescence (Figure 4.1 D),
whereas this effect was more modest in lymph nodes (Figure 4.1 E and F).
Together, these findings manifest that IV administration of RPV-NC travels via
blood to reticuloendothelial organs (i.e., liver, spleen, and lymph nodes), where
they are encountered and engulfed by various immunocytes. In contrast, IM
administration of RPV shows a very different pharmacokinetic profile according to
prior works involving a polymeric nanoformulation of RPV111.

4.3.2 Cellular tracking of RPV-NC in humanized mice
To track nanoparticles in CD4+ T cells and monocyte-macrophages, a
second murine model was employed to assess the uptake of RPV-NC in human

89
immune cells. NSG mice were reconstituted at birth with human CD34+
hematopoietic stem cells (HSC). Importantly, the reconstituted mice (humanized
mice) show quiescent lymphocyte profiles and as such reflect what would occur in
a HIV-1 challenged human host 155. These humanized mice were injected with 45
mg/kg RPV equivalent of RPV-NC, and after 24 hours, the liver and spleen were
collected. Single cell suspensions of these tissues were prepared and analyzed ex
vivo by flow cytometry for nanoparticle distribution in different immune subsets.
Figure 4.3 A shows representative flow cytometry plots of nanoparticle positive
CD4+ T cells and CD14+ macrophages from treated mice. The detailed gating
strategy for different immune subsets is provided in Figure 4.4. Human CD4+ and
CD14+ populations were quantified as percent nanoparticle positive cells for each
animal. From the same experimental mice, cellular suspensions from the liver and
spleen were subjected to fluorescence-activated cell sorting (FACS) to sort CD4+
T cells and CD14+ monocyte-macrophages. These isolated cell populations were
then analyzed by UPLC-MS/MS quantification of RPV. Figure 4.3 B shows liver
CD4+ T cell and CD14+ macrophage percent populations positive for RPV-NC.
RPV levels of about 179 ng/106 cells and 368 ng/106 cells were observed in the
CD4+ T cells and monocyte-macrophages, respectively, as shown in Figure 4.3
C. Pearson correlations between RPV levels and percent positive CD4+ T cell or
CD14+ macrophage populations provided r values of 0.81 and 0.94, respectively
(Figure 4.3 D & E). Similarly, Figure 4.3 F shows percent CD4+ T cell and
monocyte-macrophage populations positive for RPV-NC where a significantly
higher particle uptake was observed in macrophages. RPV levels of about 22.6
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ng/106 cells and 62.6 ng/106 cells were observed in splenic CD4+ T cells and
CD14+ macrophages, respectively, as shown in Figure 4.3 G. Pearson correlation
analysis for RPV concentration and percent cells positive for RPV-NC provided an
r-value of 0.72 for the CD4+ T cells and 0.99 for the monocyte-macrophages as
shown in Figure 4.3 H and I. Hence, the presence of RPV-NC in human monocytemacrophages and T cells was observed by flow cytometry and substantiated with
RPV drug levels from UPLC-MS/MS. The correlation values obtained confirm the
presence of RPV-NC in the form of intact nanoparticles in immune cell subsets.
These data, taken together, confirm that the AIE property of RPV can be used to
track the presence and integrity of RPV-NC in immune cell populations.
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4.4

Discussion
PK studies in rats and PBL-reconstituted mice showed detectable drug levels

in tissues. Following tissue drug quantification tests, we analyzed the major tissue
reservoirs of HIV: liver, spleen and lymph node ftor presence of intact nanocrystals
of RPV. Confocal analysis of rat liver tissue showed apparent co-localization of
RPV-NC in activated macrophages. Similar results were seen in human CD4+
leucocytes in spleen and lymph node tissues of PBL-reconstituted mice. Together,
these findings manifest that IV administration of RPV-NC travels via blood to
reticuloendothelial organs (i.e., liver, spleen, and lymph nodes), where they are
encountered and engulfed by various immunocytes.
Furthermore, to track RPV-NC distribution in cell subpopulations, HSCreconstituted mice, also known as, humanized mice, were used. Following
treatment for 24 hours, liver and spleen tissue were collected. Single cell
suspensions of these tissues were subjected to flow cytometry, FACS and UPLCMS/MS. Presence of RPV-NC in human monocyte-macrophages and T cells was
observed by flow cytometry and substantiated with RPV drug levels from UPLCMS/MS. The correlation values obtained confirm the presence of RPV-NC in the
form of intact nanoparticles in immune cell subsets. Taken together, these results
posit that the AIE property of RPV can be used to track the presence and integrity
of RPV-NC in immune cell populations, enabling effective and targeted delivery of
ARVs to cellular viral reservoirs.
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4.5

Figures
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Figure 4.1 PK and RPV tissue-cell biodistribution.
(A) Schematic representation of the in-vivo studies of RPV-NC. (B) RPV
concentrations from (i) rat plasma at 1, 2- and 5-days post-injection (ii) rat liver,
spleen and lymph node tissue on day 5 post-injection (iii) PBL mouse tissue on
day 10 post-injection. Statistical differences were determined using two-way
ANOVA among groups; Bonferroni's post-hoc test was used for multiple
comparisons. *p < 0.05; **p < 0.01; ***p < 0.001. (C) Representative images of rat
spleen tissue sections stained with Iba-1 for activated macrophages (green).
Yellow areas indicate co-localization of RPV-NC (pseudo-colored red) in rat
splenic macrophages. Representative images of PBL mouse (D) spleen and (E)
lymph node tissue sections, stained with anti-human CD4+ antibody (green).
Yellow areas indicate co-localization of RPV-NC (pseudo-colored red) in human
CD4+ cells. (F) Magnification of the areas of co-localization from (E). Nuclei are
stained with NucRed (pseudo-colored blue).
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Figure 4.2 Evaluation of RPV-NC toxicity.
(A) Hepatic, renal and pancreatic functions were analyzed in rats 5 days postinjection of RPV-NC administered IV at 45 mg/kg (ALB: Albumin, ALP: Alkaline
phosphatase, TBIL: Total bilirubin, BUN: Blood urea nitrogen, TP: Total protein,
CRE: creatinine). (B) Hematoxylin and eosin staining of rat tissues. Normal tissue
histology was recorded in tissues in all animal groups. Images were captured with
a 20x magnification objective.
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Figure 4.3 Nanoparticle tracking and quantification in humanized mice.
(A) Representative flow cytometry plots showing RPV-NC positive populations in
spleen CD4+ T cells and CD14+ macrophages based on gating relative to
splenocytes and hepatocytes from untreated control mice (see Figure 4.4 for full
gating description). (B) Percent populations positive for RPV-NC from the liver. (C)
RPV concentrations in hepatic T cells and macrophages. Pearson correlation
between RPV-NC percent positive population and RPV drug levels in liver (D) T
cells; r = 0.81 and (E) macrophages; r = 0.93 (F) Percent populations positive for
RPV-NC from the spleen. (G) RPV concentrations in splenic T cells and
macrophages. Pearson correlation between RPV-NC percent positive population
and RPV drug levels in splenic (H) T cells; r = 0.72 and (I) macrophages; r = 0.97.
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Figure 4.4 Gating strategy for in vivo tracking of RPV-NC in humanized mice.
CD45 (pan-leukocyte) marker was used differentiate human- from murine cells.
CD45+ populations were then sub-gated into CD14+ (monocyte-macrophage) and
CD3+ (T lymphocyte) populations. CD3+ populations were then sub-gated into
CD4+ and CD8+ populations. Gates for RPV-NC positive populations were drawn
based on plots from untreated control mice.
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CHAPTER 5. DISCUSSION
Treatment for HIV/AIDS has made significant progress since its first
descriptions in the early 1980s5, 11-13, 17, 156. ART readily suppresses viral replication
to undetectable levels and improves the quality and longevity of life157-159. The
recent emergence of LA ART extends the prior ART successes and has led to
improvements in treatment regimens and patient adherence as well as prevent
new viral infections156. While viral suppression and restoration of immunity have
been observed, elimination of the viral reservoir has not yet been achieved.
Nonetheless, a number of research strategies are being developed towards HIV
cure. This includes improved ART, viral reversal agents and boosting of adaptive
immunity. These have been deployed to modulate viral replication then eliminate
the residual infected cells. Recent progress has been achieved in this field with
LASER ART being able to extend plasma drug levels up to months upon a single
injection7, 8, 138. Further advances have also been able to eliminate HIV in animal
models using a combination of LASER ART and CRISPR-Cas 9 excision
systems14. One of the major hurdles involving efforts to cure HIV lies in the latent
viral reservoirs that develop in tissues and cells16, 18, 19, 31. It has been well-known
that the major cellular reservoirs of latent HIV infection are the CD4+ T cells104-106.
Since the major leukocyte harboring latent HIV infection is the CD4+ T cell

104-106

and to a lesser degree the monocyte-macrophage, tracking of viral cell reservoirs
is imperative to seek out sites of low-level HIV replication so that viral elimination
can be achieved. While such cell tracking could be achieved through gold,
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magnetic and programmed nanoparticles 76, 87, 90 concerns for both sensitivity and
specificity of such systems abound. AIE could overcome such limitations as it
allows for visualization of ARVs or excision-containing nanoparticles endocytosed
by these cellular reservoirs as well as simultaneously permitting quantitative drug
assessment.
To effectively achieve viral elimination, therapeutically effective amounts of
viral suppressive and elimination agents must reach cellular reservoirs of HIV.
Thus, ARV tracking to sites of viral infection is required. The development of RPVNC exhibiting AIE could enable this need to be achieved. Correlations made
between amount of therapeutic nanoparticle payloads delivered to cells harboring
latent HIV and elimination of infection could be realized. Thus, the technologies
developed herein would provide a pathway forward towards such required
therapeutic delivery. Indeed, molecules with AIE properties have already shown to
possess a wide range of applications. These include chemical sensors to biological
imaging probes and have been used successfully in a range of applications in
diagnosis and therapy

65, 80, 81, 160, 161

tetraphenylethylene (TPE)

68, 70, 71, 81

. One such prototypical molecule is

. The AIE characteristics of TPE were

deployed as an AIE fluorescent probe for real time tracking of cell apoptosis

162

.

Other molecules have been derivatized by introducing an AIE-genic fragment to
induce strong fluorescence upon aggregation 73, 74. Clearly, the future use of AIEactive drugs will certainly provide significant added advantages to any presently
existing nanoparticle tracking designs.
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In this work, we report a novel aggregation-induced emission property of
RPV. RPV, an NNRTI that is being used for HIV therapy, exhibits fluorescence
emission at 350nm when aggregated. Hence, we hypothesized that the AIE
property of RPV can be used as an effective tool to assess nanoparticle integrity
and achieve nanoparticle tracking in cellular sub-populations while also achieving
therapeutic outcomes. To achieve this goal, we formulated RPV nanocrystals,
characterized their AIE phenomenon and utilized them to track nanoparticle
presence in HIV targeted cell populations. First, we synthesized RPV-NC through
a bottom-up top-down approach by antisolvent precipitation and subsequent sizereduction to obtain nanoparticles that can reach viral target CD4+ T cells and
monocyte-macrophages. Second, we thoroughly characterized the morphological
and fluorescent properties of RPV-NC in a wide variety of conditions. These
characterizations confirmed the AIE property of RPV as well as the crystallinity of
formulated RPV-NC. Third, we performed single crystal x-ray crystallography
studies and found that RIR was the primary mechanism of AIE expression in RPVNC. Fourth, we characterized the uptake of RPV-NC in CD14+ macrophages and
CD4+ T cells with a broad range of techniques and also ensured cell uptake of
RPV-NC in simulated conditions that could reflect what is operative in an HIV
infected human host. Fifth, we carried out confocal microscopy analyses of
macrophages and T cells treated with RPV-NC and confirmed their presence in
cellular and sub-cellular compartments where viral replication is known to ensue.
Sixth, PK and biodistribution studies were performed and showed the presence of
RPV in liver, spleen and lymph nodes which are major tissue viral reservoirs.
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Seventh, confocal analyses of these tissue sections showed the presence of intact
RPV-NC in splenic macrophages and human CD4+ T cells of the spleen and lymph
node. Eighth, nanoparticle tracking was achieved by flow cytometry in human
immune cells using a humanized mouse model. CD4+ T cells and monocytemacrophages from these animals were isolated by FACS and subjected to drug
quantification. These results, taken together, demonstrate the use of AIE to
achieve therapeutic nanoparticle tracking in human cellular immune subsets.
All together, we characterized an AIE drug molecule, RPV, and harnessed its
fluorescent property for drug biodistribution assessments. Cellular uptake studies
were translated into animal models to observe nanoparticle tracking in CD4+ T
cells and monocyte-macrophages. When used in combination with other ARVs 156,
163

, RPV has the potential to track the biodistribution and cellular uptake of other

drugs. In tandem with drug quantification, the AIE phenomena can be used as a
platform to optimize drug delivery to cellular viral reservoirs that currently remain
elusive. While parallel studies have achieved cellular tracking for other diseases
by gold, magnetic and programmed nanoparticles

76, 87, 90

, the inherent AIE

property of RPV enables simultaneous assessment by fluorescence and drug
quantification, affirming the presence of intact ARV nanoparticles in target cellular
reservoirs. Our findings may be readily translated into other nanoformulations and
can be used with other AIE molecules to achieve nanoparticle tracking to deliver
ARV to viral reservoir sites and aid in achieving HIV eradication through continuous
improvement of antiretroviral therapies.
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